{
    "abstract": "Blood contact with biomaterials triggers activation of multiple reactive mechanisms that can impair the performance of implantable medical devices and potentially cause serious adverse clinical events. This includes thrombosis and thromboembolic complications due to activation of platelets and the coagulation cascade, activation of the complement system, and inflammation. Numerous surface coatings have been developed to improve blood compatibility of biomaterials. For more than thirty years, the anticoagulant drug heparin has been employed as a covalently immobilized surface coating on a variety of medical devices. This review describes the fundamental principles of non-eluting heparin coatings, mechanisms of action, and clinical applications with focus on those technologies which have been commercialized. Because of its extensive publication history, there is emphasis on the CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface), a widely used commercialized technology for the covalent bonding of heparin.",
    "bib_entries": {
        "bb0005": {
            "authors": [
                {
                    "first": "Maud B.",
                    "initial": "M.B.",
                    "last": "Gorbet"
                },
                {
                    "first": "Michael V.",
                    "initial": "M.V.",
                    "last": "Sefton"
                }
            ],
            "doi": "10.1016/j.biomaterials.2004.01.023",
            "firstpage": "5681",
            "issn": "01429612",
            "lastpage": "5703",
            "pmid": "15147815",
            "pub_year": 2004,
            "title": "Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes",
            "volume": "25"
        },
        "bb0010": {
            "authors": [
                {
                    "first": "I. H.",
                    "initial": "I.H.",
                    "last": "Jaffer"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Fredenburgh"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hirsh"
                },
                {
                    "first": "J. I.",
                    "initial": "J.I.",
                    "last": "Weitz"
                }
            ],
            "doi": "10.1111/jth.12961",
            "firstpage": "S72",
            "issn": "15387933",
            "lastpage": "S81",
            "pmid": "26149053",
            "pub_year": 2015,
            "title": "Medical device-induced thrombosis: What causes it and how can we prevent it?",
            "volume": "13"
        },
        "bb0015": {
            "authors": [
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "Tanzi"
                }
            ],
            "doi": "10.1586/17434440.2.4.473",
            "firstpage": "473",
            "issn": "17434440",
            "lastpage": "492",
            "pmid": "16293086",
            "pub_year": 2005,
            "title": "Bioactive technologies for hemocompatibility",
            "volume": "2"
        },
        "bb0020": {
            "authors": [
                {
                    "first": "Vincent L.",
                    "initial": "V.L.",
                    "last": "Gott"
                },
                {
                    "first": "James D.",
                    "initial": "J.D.",
                    "last": "Whiffen"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Dutton"
                }
            ],
            "firstpage": "1299",
            "issn": "00368075",
            "lastpage": "1300",
            "pmid": "14074839",
            "pub_year": 1963,
            "title": "Heparin bonding on colloidal graphite surfaces",
            "volume": "142"
        },
        "bb0025": {
            "authors": [
                {
                    "first": "Hans Peter",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Ziemer"
                }
            ],
            "doi": "10.1016/S1010-7940(99)00210-9",
            "firstpage": "342",
            "issn": "10107940",
            "lastpage": "350",
            "pmid": "10554855",
            "pub_year": 1999,
            "title": "Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation",
            "volume": "16"
        },
        "bb0030": null,
        "bb0035": {
            "authors": [
                {
                    "first": "Saravanababu",
                    "initial": "S.",
                    "last": "Murugesan"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Xie"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Linhardt"
                }
            ],
            "doi": "10.2174/156802608783378891",
            "firstpage": "80",
            "issn": "15680266",
            "lastpage": "100",
            "pmid": "18289079",
            "pub_year": 2008,
            "title": "Immobilization of heparin: Approaches and applications",
            "volume": "8"
        },
        "bb0040": {
            "authors": [
                {
                    "first": "Shelly E.",
                    "initial": "S.E.",
                    "last": "Sakiyama-Elbert"
                }
            ],
            "doi": "10.1016/j.actbio.2013.08.045",
            "firstpage": "1581",
            "issn": "17427061",
            "lastpage": "1587",
            "pmid": "24021232",
            "pub_year": 2014,
            "title": "Incorporation of heparin into biomaterials",
            "volume": "10"
        },
        "bb0045": {
            "authors": [
                {
                    "first": "H. T.",
                    "initial": "H.T.",
                    "last": "Spijker"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Graaff"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Boonstra"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Busscher"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Van Oeveren"
                }
            ],
            "doi": "10.1016/S0142-9612(03)00380-6",
            "firstpage": "4717",
            "issn": "01429612",
            "lastpage": "4727",
            "pmid": "14530069",
            "pub_year": 2003,
            "title": "On the influence of flow conditions and wettability on blood material interactions",
            "volume": "24"
        },
        "bb0050": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Blockmans"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Deckmyn"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Vermylen"
                }
            ],
            "doi": "10.1016/0268-960X(95)90020-9",
            "firstpage": "143",
            "issn": "0268960X",
            "lastpage": "156",
            "pmid": "8563516",
            "pub_year": 1995,
            "title": "Platelet actuation",
            "volume": "9"
        },
        "bb0055": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Bach"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Nemerson"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Konigsberg"
                }
            ],
            "firstpage": "8324",
            "issn": "00219258",
            "lastpage": "8331",
            "pmid": "6790539",
            "pub_year": 1981,
            "title": "Purification and characterization of bovine tissue factor.",
            "volume": "256"
        },
        "bb0060": {
            "authors": [
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Holmer"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kurachi"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Soderstrom"
                }
            ],
            "doi": "10.1042/bj1930395",
            "firstpage": "395",
            "issn": "02646021",
            "lastpage": "400",
            "pmid": "6914196",
            "pub_year": 1981,
            "title": "The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin",
            "volume": "193"
        },
        "bb0065": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Bourin"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Lindahl"
                }
            ],
            "doi": "10.1042/bj2890313",
            "firstpage": "313",
            "issn": "02646021",
            "lastpage": "330",
            "pmid": "8380990",
            "pub_year": 1993,
            "title": "Glycosaminoglycans and the regulation of blood coagulation",
            "volume": "289"
        },
        "bb0070": {
            "authors": [
                {
                    "first": "A. I.",
                    "initial": "A.I.",
                    "last": "De Agostini"
                },
                {
                    "first": "S. C.",
                    "initial": "S.C.",
                    "last": "Watkins"
                },
                {
                    "first": "H. S.",
                    "initial": "H.S.",
                    "last": "Slayter"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Youssoufian"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Rosenberg"
                }
            ],
            "doi": "10.1083/jcb.111.3.1293",
            "firstpage": "1293",
            "issn": "00219525",
            "lastpage": "1304",
            "pmid": "2144002",
            "pub_year": 1990,
            "title": "Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta",
            "volume": "111"
        },
        "bb0075": {
            "authors": [
                {
                    "first": "Lennart",
                    "initial": "L.",
                    "last": "Thunberg"
                },
                {
                    "first": "Gudrun",
                    "initial": "G.",
                    "last": "B\u00e4ckstr\u00f6m"
                },
                {
                    "first": "Ulf",
                    "initial": "U.",
                    "last": "Lindahl"
                }
            ],
            "doi": "10.1016/S0008-6215(00)81050-2",
            "firstpage": "393",
            "issn": "00086215",
            "lastpage": "410",
            "pmid": "7083257",
            "pub_year": 1982,
            "title": "Further characterization of the antithrombin-binding sequence in heparin",
            "volume": "100"
        },
        "bb0080": {
            "authors": [
                {
                    "first": "L. O.",
                    "initial": "L.O.",
                    "last": "Andersson"
                },
                {
                    "first": "T. W.",
                    "initial": "T.W.",
                    "last": "Barrowcliffe"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Holmer"
                },
                {
                    "first": "E. A.",
                    "initial": "E.A.",
                    "last": "Johnson"
                },
                {
                    "first": "G. E.C.",
                    "initial": "G.E.C.",
                    "last": "Sims"
                }
            ],
            "doi": "10.1016/0049-3848(76)90105-5",
            "firstpage": "575",
            "issn": "00493848",
            "lastpage": "583",
            "pub_year": 1976,
            "title": "Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration",
            "volume": "9"
        },
        "bb0085": {
            "authors": [
                {
                    "first": "Magnus",
                    "initial": "M.",
                    "last": "H\u00f6\u00f6k"
                },
                {
                    "first": "Ingemar",
                    "initial": "I.",
                    "last": "Bj\u00f6rk"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Hopwood"
                },
                {
                    "first": "Ulf",
                    "initial": "U.",
                    "last": "Lindahl"
                }
            ],
            "doi": "10.1016/0014-5793(76)80592-3",
            "firstpage": "90",
            "issn": "00145793",
            "lastpage": "93",
            "pmid": "1278445",
            "pub_year": 1976,
            "title": "Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin",
            "volume": "66"
        },
        "bb0090": {
            "authors": [
                {
                    "first": "L. H.",
                    "initial": "L.H.",
                    "last": "Lam"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Silbert"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Rosenberg"
                }
            ],
            "doi": "10.1016/0006-291X(76)90558-1",
            "firstpage": "570",
            "issn": "0006291X",
            "lastpage": "577",
            "pmid": "1267803",
            "pub_year": 1976,
            "title": "The separation of active and inactive forms of heparin",
            "volume": "69"
        },
        "bb0095": {
            "authors": [
                {
                    "first": "Per",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Lagergren"
                },
                {
                    "first": "Stig",
                    "initial": "S.",
                    "last": "Ek"
                }
            ],
            "doi": "10.1111/j.0954-6820.1963.tb17446.x",
            "firstpage": "619",
            "issn": "00016101",
            "lastpage": "630",
            "pmid": "13940090",
            "pub_year": 1963,
            "title": "The Elimination from Plasma of Intravenous Heparin An Experimental Study on Dogs and Humans",
            "volume": "173"
        },
        "bb0100": {
            "authors": [
                {
                    "first": "Thorir D.",
                    "initial": "T.D.",
                    "last": "Bjornsson"
                },
                {
                    "first": "Katherine M.",
                    "initial": "K.M.",
                    "last": "Wolfram"
                },
                {
                    "first": "Barbara B.",
                    "initial": "B.B.",
                    "last": "Kitchell"
                }
            ],
            "doi": "10.1038/clpt.1982.16",
            "firstpage": "104",
            "issn": "00099236",
            "lastpage": "113",
            "pmid": "7053298",
            "pub_year": 1982,
            "title": "Heparin kinetics determined by three assay methods",
            "volume": "31"
        },
        "bb0105": {
            "authors": [
                {
                    "first": "C. A.M.",
                    "initial": "C.A.M.",
                    "last": "De Swart"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Nijmeyer"
                },
                {
                    "first": "J. M.M.",
                    "initial": "J.M.M.",
                    "last": "Roelofs"
                },
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Sixma"
                }
            ],
            "firstpage": "1251",
            "issn": "00064971",
            "lastpage": "1258",
            "pmid": "7139119",
            "pub_year": 1982,
            "title": "Kinetics of intravenously administered heparin in normal humans",
            "volume": "60"
        },
        "bb0110": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Mahadoo"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Hiebert"
                },
                {
                    "first": "L. B.",
                    "initial": "L.B.",
                    "last": "Jaques"
                }
            ],
            "doi": "10.1016/0049-3848(78)90087-7",
            "firstpage": "79",
            "issn": "00493848",
            "lastpage": "90",
            "pmid": "644562",
            "pub_year": 1978,
            "title": "Vascular sequestration of heparin",
            "volume": "12"
        },
        "bb0115": {
            "authors": [
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Dawes"
                },
                {
                    "first": "Duncan S.",
                    "initial": "D.S.",
                    "last": "Pepper"
                }
            ],
            "doi": "10.1016/0049-3848(79)90004-5",
            "firstpage": "845",
            "issn": "00493848",
            "lastpage": "860",
            "pmid": "473122",
            "pub_year": 1979,
            "title": "Catabolism of low-dose heparin in man",
            "volume": "14"
        },
        "bb0120": {
            "authors": [
                {
                    "first": "Jack N.",
                    "initial": "J.N.",
                    "last": "Lindon"
                },
                {
                    "first": "Edwin W.",
                    "initial": "E.W.",
                    "last": "Salzman"
                },
                {
                    "first": "Edward W.",
                    "initial": "E.W.",
                    "last": "Merrill"
                },
                {
                    "first": "Ali K.",
                    "initial": "A.K.",
                    "last": "Dincer"
                },
                {
                    "first": "Denis",
                    "initial": "D.",
                    "last": "Labarre"
                },
                {
                    "first": "Kenneth A.",
                    "initial": "K.A.",
                    "last": "Bauer"
                },
                {
                    "first": "Robert R.",
                    "initial": "R.R.",
                    "last": "Rosenberg"
                }
            ],
            "firstpage": "214",
            "issn": "00222143",
            "lastpage": "218",
            "pmid": "3973461",
            "pub_year": 1985,
            "title": "Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces",
            "volume": "105"
        },
        "bb0125": {
            "authors": [
                {
                    "first": "Savannah",
                    "initial": "S.",
                    "last": "Gore"
                },
                {
                    "first": "Jonas",
                    "initial": "J.",
                    "last": "Andersson"
                },
                {
                    "first": "Roy",
                    "initial": "R.",
                    "last": "Biran"
                },
                {
                    "first": "Clayton",
                    "initial": "C.",
                    "last": "Underwood"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Riesenfeld"
                }
            ],
            "doi": "10.1002/jbm.b.33154",
            "firstpage": "1817",
            "issn": "15524973",
            "lastpage": "1824",
            "pmid": "24711209",
            "pub_year": 2014,
            "title": "Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption",
            "volume": "102"
        },
        "bb0130": {
            "authors": [
                {
                    "first": "Tasneem",
                    "initial": "T.",
                    "last": "Islam"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Butler"
                },
                {
                    "first": "Sulthan A.",
                    "initial": "S.A.",
                    "last": "Sikkander"
                },
                {
                    "first": "Toshihiko",
                    "initial": "T.",
                    "last": "Toida"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Linhardt"
                }
            ],
            "doi": "10.1016/S0008-6215(02)00229-X",
            "firstpage": "2239",
            "issn": "00086215",
            "lastpage": "2243",
            "pmid": "12433488",
            "pub_year": 2002,
            "title": "Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site",
            "volume": "337"
        },
        "bb0135": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Blomback"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                }
            ],
            "doi": "10.1055/s-0038-1649568",
            "firstpage": "289",
            "issn": "03406245",
            "lastpage": "293",
            "pmid": "8236137",
            "pub_year": 1993,
            "title": "On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin",
            "volume": "70"
        },
        "bb0140": {
            "authors": [
                {
                    "first": "Shivpal",
                    "initial": "S.",
                    "last": "Sandhu"
                },
                {
                    "first": "Ajay",
                    "initial": "A.",
                    "last": "Luthra"
                }
            ],
            "firstpage": "10",
            "issn": "10486690",
            "lastpage": "16",
            "pmid": "2002137219",
            "pub_year": 2002,
            "title": "New biointeracting materials.",
            "volume": "13"
        },
        "bb0145": null,
        "bb0150": {
            "authors": [
                {
                    "first": "Eiki",
                    "initial": "E.",
                    "last": "Tayama"
                },
                {
                    "first": "Nobuhiko",
                    "initial": "N.",
                    "last": "Hayashida"
                },
                {
                    "first": "Koji",
                    "initial": "K.",
                    "last": "Akasu"
                },
                {
                    "first": "Tomokazu",
                    "initial": "T.",
                    "last": "Kosuga"
                },
                {
                    "first": "Shyuji",
                    "initial": "S.",
                    "last": "Fukunaga"
                },
                {
                    "first": "Hidetoshi",
                    "initial": "H.",
                    "last": "Akashi"
                },
                {
                    "first": "Takemi",
                    "initial": "T.",
                    "last": "Kawara"
                },
                {
                    "first": "Shigeaki",
                    "initial": "S.",
                    "last": "Aoyagi"
                }
            ],
            "doi": "10.1046/j.1525-1594.2000.06615.x",
            "firstpage": "618",
            "issn": "0160564X",
            "lastpage": "623",
            "pmid": "10971248",
            "pub_year": 2000,
            "title": "Biocompatibility of heparin-coated extracorporeal bypass circuits: New heparin bonded bioline system",
            "volume": "24"
        },
        "bb0155": null,
        "bb0160": {
            "authors": [
                {
                    "first": "E. M.E.",
                    "initial": "E.M.E.",
                    "last": "Kristensen"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Rensmo"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Larsson"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Siegbahn"
                }
            ],
            "doi": "10.1016/S0142-9612(03)00297-7",
            "firstpage": "4153",
            "issn": "01429612",
            "lastpage": "4159",
            "pmid": "12853245",
            "pub_year": 2003,
            "title": "Characterization of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance",
            "volume": "24"
        },
        "bb0165": {
            "authors": [
                {
                    "first": "Matilda",
                    "initial": "M.",
                    "last": "Johnell"
                },
                {
                    "first": "Graciela",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "Rolf",
                    "initial": "R.",
                    "last": "Larsson"
                },
                {
                    "first": "Anders",
                    "initial": "A.",
                    "last": "Larsson"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Thelin"
                },
                {
                    "first": "Agneta",
                    "initial": "A.",
                    "last": "Siegbahn"
                }
            ],
            "doi": "10.1067/mtc.2002.122551",
            "firstpage": "321",
            "issn": "00225223",
            "lastpage": "332",
            "pmid": "12167793",
            "pub_year": 2002,
            "title": "Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface",
            "volume": "124"
        },
        "bb0170": {
            "authors": [
                {
                    "first": "Jonas",
                    "initial": "J.",
                    "last": "Andersson"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "Kristina Nilsson",
                    "initial": "K.N.",
                    "last": "Ekdahl"
                },
                {
                    "first": "Graciela",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Nilsson"
                },
                {
                    "first": "Rolf",
                    "initial": "R.",
                    "last": "Larsson"
                }
            ],
            "doi": "10.1002/jbm.a.10104",
            "firstpage": "458",
            "issn": "00219304",
            "lastpage": "466",
            "pmid": "14566786",
            "pub_year": 2003,
            "title": "Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro",
            "volume": "67"
        },
        "bb0175": {
            "authors": [
                {
                    "first": "Rena M.",
                    "initial": "R.M.",
                    "last": "Cornelius"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "Per",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Brash"
                }
            ],
            "doi": "10.1002/jbm.a.10118",
            "firstpage": "475",
            "issn": "00219304",
            "lastpage": "483",
            "pmid": "14566788",
            "pub_year": 2003,
            "title": "Interactions of antithrombin and proteins in the plasma contact activation system with immobilized functional heparin",
            "volume": "67"
        },
        "bb0180": {
            "authors": [
                {
                    "first": "Muhammad A.",
                    "initial": "M.A.",
                    "last": "Lodhi"
                },
                {
                    "first": "Gary W.",
                    "initial": "G.W.",
                    "last": "Opperman"
                },
                {
                    "first": "John V.",
                    "initial": "J.V.",
                    "last": "Wall"
                },
                {
                    "first": "Aron B.",
                    "initial": "A.B.",
                    "last": "Anderson"
                }
            ],
            "firstpage": "389",
            "lastpage": "392",
            "pub_year": 2005,
            "title": "Surface modification chemistries and their utilization in microarrays, diagnostics and drug delivery"
        },
        "bb0185": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Blezer"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Cahalan"
                },
                {
                    "first": "P. T.",
                    "initial": "P.T.",
                    "last": "Cahalan"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Lindhout"
                }
            ],
            "doi": "10.1097/00001721-199807000-00006",
            "firstpage": "435",
            "issn": "09575235",
            "lastpage": "440",
            "pmid": "9712292",
            "pub_year": 1998,
            "title": "Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation",
            "volume": "9"
        },
        "bb0190": null,
        "bb0195": {
            "authors": [
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Larm"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Larsson"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                }
            ],
            "doi": "10.3109/10731198309118804",
            "firstpage": "161",
            "issn": "00905488",
            "lastpage": "173",
            "pmid": "6667322",
            "pub_year": 1983,
            "title": "A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue",
            "volume": "11"
        },
        "bb0200": null,
        "bb0205": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kodama"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Pasche"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Swedenborg"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Adolfsson"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Larm"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                }
            ],
            "doi": "10.1055/s-0038-1646057",
            "firstpage": "1064",
            "issn": "03406245",
            "lastpage": "1067",
            "pmid": "3481885",
            "pub_year": 1987,
            "title": "Antithrombin III binding to surface immobilized heparin and its relation to F Xa inhibition",
            "volume": "58"
        },
        "bb0210": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                }
            ],
            "doi": "10.1002/(SICI)1097-4636(199710)37:1<37::AID-JBM5>3.0.CO;2-K",
            "firstpage": "37",
            "issn": "00219304",
            "lastpage": "42",
            "pmid": "9335347",
            "pub_year": 1997,
            "title": "Inhibition of the plasma contact activation system of immobilized heparin: Relation to surface density of functional antithrombin binding sites",
            "volume": "37"
        },
        "bb0215": {
            "authors": [
                {
                    "first": "P. C.",
                    "initial": "P.C.",
                    "last": "Begovac"
                },
                {
                    "first": "R. C.",
                    "initial": "R.C.",
                    "last": "Thomson"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Fisher"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Hughson"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "G\u00e4llhagen"
                }
            ],
            "doi": "10.1053/ejvs.2002.1909",
            "firstpage": "432",
            "issn": "10785884",
            "lastpage": "437",
            "pmid": "12713782",
            "pub_year": 2003,
            "title": "Improvements in GORE-TEX\u00ae vascular graft performance by Carmeda\u00ae BioActive Surface heparin immobilization",
            "volume": "25"
        },
        "bb0220": {
            "authors": [
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Kocsis"
                },
                {
                    "first": "Gerard",
                    "initial": "G.",
                    "last": "Llanos"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Holmer"
                }
            ],
            "doi": "10.1615/JLongTermEffMedImplants.v10.i12.50",
            "firstpage": "19",
            "issn": "10506934",
            "lastpage": "45",
            "pmid": "10947628",
            "pub_year": 2000,
            "title": "Heparin-Coated stents",
            "volume": "10"
        },
        "bb0225": {
            "authors": [
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Lindhout"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Blezer"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Schoen"
                },
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Willems"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Fouache"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Verhoeven"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Hendriks"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Cahalan"
                },
                {
                    "first": "P. T.",
                    "initial": "P.T.",
                    "last": "Cahalan"
                }
            ],
            "doi": "10.1002/jbm.820291013",
            "firstpage": "1255",
            "issn": "00219304",
            "lastpage": "1266",
            "pmid": "8557728",
            "pub_year": 1995,
            "title": "Antithrombin activity of surface\u2010bound heparin studied under flow conditions",
            "volume": "29"
        },
        "bb0230": {
            "authors": [
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Pasche"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Rasmuson"
                }
            ],
            "firstpage": "481",
            "issn": "0160564X",
            "lastpage": "491",
            "pmid": "1763970",
            "pub_year": 1991,
            "title": "Binding of antithrombin to immobilized heparin under varying flow conditions",
            "volume": "15"
        },
        "bb0235": {
            "authors": [
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Pasche"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kodama"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Larm"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Swedenborg"
                }
            ],
            "doi": "10.1016/0049-3848(86)90020-4",
            "firstpage": "739",
            "issn": "00493848",
            "lastpage": "748",
            "pmid": "3798418",
            "pub_year": 1986,
            "title": "Thrombin inactivation on surfaces with covalently bonded heparin",
            "volume": "44"
        },
        "bb0240": {
            "authors": [
                {
                    "first": "Hans P.",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "Albertus M.",
                    "initial": "A.M.",
                    "last": "Scheule"
                },
                {
                    "first": "Friedrich S.",
                    "initial": "F.S.",
                    "last": "Eckstein"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Ziemer"
                }
            ],
            "doi": "10.1177/026765919901400104",
            "firstpage": "21",
            "issn": "02676591",
            "lastpage": "28",
            "pmid": "10074643",
            "pub_year": 1999,
            "title": "Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces",
            "volume": "14"
        },
        "bb0245": {
            "authors": [
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "Graciela",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "Per",
                    "initial": "P.",
                    "last": "Olsson"
                }
            ],
            "doi": "10.1016/S0049-3848(97)00310-1",
            "firstpage": "41",
            "issn": "00493848",
            "lastpage": "50",
            "pmid": "9610759",
            "pub_year": 1998,
            "title": "Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin",
            "volume": "89"
        },
        "bb0250": {
            "authors": [
                {
                    "first": "Alvin H.",
                    "initial": "A.H.",
                    "last": "Schmaier"
                }
            ],
            "firstpage": "101",
            "issn": "03406245",
            "lastpage": "107",
            "pmid": "9198136",
            "pub_year": 1997,
            "title": "Contact activation: A revision",
            "volume": "78"
        },
        "bb0255": {
            "authors": [
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Nilsson"
                },
                {
                    "first": "Kristina Nilsson",
                    "initial": "K.N.",
                    "last": "Ekdahl"
                },
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Lambris"
                }
            ],
            "doi": "10.1016/j.molimm.2006.06.020",
            "firstpage": "82",
            "issn": "01615890",
            "lastpage": "94",
            "pmid": "16905192",
            "pub_year": 2007,
            "title": "The role of complement in biomaterial-induced inflammation",
            "volume": "44"
        },
        "bb0260": {
            "authors": [
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Videm"
                },
                {
                    "first": "T. E.",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Garred"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Svennevig"
                }
            ],
            "doi": "10.1016/s0022-5223(19)36696-6",
            "firstpage": "654",
            "issn": "00225223",
            "lastpage": "660",
            "pmid": "2008104",
            "pub_year": 1991,
            "title": "Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits",
            "volume": "101"
        },
        "bb0265": {
            "authors": [
                {
                    "first": "U. R.",
                    "initial": "U.R.",
                    "last": "NILSSON"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "LARM"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "NILSSON"
                },
                {
                    "first": "K. \u2010E",
                    "initial": "K.\u2010.",
                    "last": "STORM"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "ELWING"
                },
                {
                    "first": "K. NILSSON",
                    "initial": "K.N.",
                    "last": "EKDAHL"
                }
            ],
            "doi": "10.1111/j.1365-3083.1993.tb02564.x",
            "firstpage": "349",
            "issn": "03009475",
            "lastpage": "354",
            "pmid": "8441922",
            "pub_year": 1993,
            "title": "Modification of the Complement Binding Properties of Polystyrene: Effects of End\u2010Point Heparin Attachment",
            "volume": "37"
        },
        "bb0270": {
            "authors": [
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "Vibeke",
                    "initial": "V.",
                    "last": "Videm"
                },
                {
                    "first": "Otto",
                    "initial": "O.",
                    "last": "G\u00f6tze"
                },
                {
                    "first": "Morten",
                    "initial": "M.",
                    "last": "Harboe"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Oppermann"
                }
            ],
            "doi": "10.1016/0003-4975(91)91426-V",
            "firstpage": "92",
            "issn": "00034975",
            "lastpage": "97",
            "pmid": "2069469",
            "pub_year": 1991,
            "title": "Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin",
            "volume": "52"
        },
        "bb0275": {
            "authors": [
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Garred"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Nordstr\u00f6m"
                },
                {
                    "first": "Kolbj\u00f8rn",
                    "initial": "K.",
                    "last": "H\u00f8g\u00e5sen"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Fosse"
                },
                {
                    "first": "Otto",
                    "initial": "O.",
                    "last": "G\u00f6tze"
                },
                {
                    "first": "Morten",
                    "initial": "M.",
                    "last": "Harboe"
                }
            ],
            "doi": "10.1111/j.1525-1594.1995.tb02450.x",
            "firstpage": "909",
            "issn": "0160564X",
            "lastpage": "917",
            "pmid": "8687297",
            "pub_year": 1995,
            "title": "A New Model for Evaluation of Biocompatibility: Combined Determination of Neoepitopes in Blood and on Artificial Surfaces Demonstrates Reduced Complement Activation by Immobilization of Heparin",
            "volume": "19"
        },
        "bb0280": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kirschfink"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Kovacs"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Mottaghy"
                }
            ],
            "firstpage": "221",
            "issn": "00926213",
            "lastpage": "226",
            "pmid": "8348684",
            "pub_year": 1993,
            "title": "Extracorporeal circulation: In vivo and in vitro analysis of complement activation by heparin-bonded surfaces",
            "volume": "40"
        },
        "bb0285": {
            "authors": [
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Weber"
                },
                {
                    "first": "H. P.",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Ziemer"
                }
            ],
            "doi": "10.1106/DUYU-CEL6-529C-WUL9",
            "firstpage": "8",
            "issn": "08853282",
            "lastpage": "22",
            "pmid": "10972157",
            "pub_year": 2000,
            "title": "Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes",
            "volume": "15"
        },
        "bb0290": {
            "authors": [
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Weber"
                },
                {
                    "first": "Hans P.",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Ziemer"
                }
            ],
            "doi": "10.1016/S0142-9612(01)00122-3",
            "firstpage": "429",
            "issn": "01429612",
            "lastpage": "439",
            "pmid": "11761163",
            "pub_year": 2002,
            "title": "Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption",
            "volume": "23"
        },
        "bb0295": {
            "authors": [
                {
                    "first": "Ruedger",
                    "initial": "R.",
                    "last": "Kopp"
                },
                {
                    "first": "Khosrow",
                    "initial": "K.",
                    "last": "Mottaghy"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Kirschfink"
                }
            ],
            "doi": "10.1097/00002480-200211000-00005",
            "firstpage": "598",
            "issn": "10582916",
            "lastpage": "605",
            "pmid": "12455769",
            "pub_year": 2002,
            "title": "Mechanism of complement activation during extracorporeal blood-biomaterial interaction: Effects of heparin coated and uncoated surfaces",
            "volume": "48"
        },
        "bb0300": {
            "authors": [
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Garred"
                },
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                }
            ],
            "firstpage": "293",
            "issn": "0160564X",
            "lastpage": "299",
            "pmid": "9096801",
            "pub_year": 1997,
            "title": "Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules",
            "volume": "21"
        },
        "bb0305": {
            "authors": [
                {
                    "first": "H. E.",
                    "initial": "H.E.",
                    "last": "H\u00f8gevold"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Moen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Fosse"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Venge"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Br\u00e5ten"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Andersson"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Lyberg"
                }
            ],
            "doi": "10.1177/026765919701200103",
            "firstpage": "9",
            "issn": "02676591",
            "lastpage": "20",
            "pub_year": 1997,
            "title": "Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro",
            "volume": "12"
        },
        "bb0310": {
            "authors": [
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "Vibeke",
                    "initial": "V.",
                    "last": "Videm"
                },
                {
                    "first": "Dorte",
                    "initial": "D.",
                    "last": "Christiansen"
                },
                {
                    "first": "Grethe",
                    "initial": "G.",
                    "last": "Bergseth"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "Torstein",
                    "initial": "T.",
                    "last": "Hovig"
                }
            ],
            "firstpage": "1132",
            "issn": "03406245",
            "lastpage": "1136",
            "pmid": "10494777",
            "pub_year": 1999,
            "title": "Platelet compatibility of an artificial surface modified with functionally active heparin",
            "volume": "82"
        },
        "bb0315": {
            "authors": [
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Stenach"
                },
                {
                    "first": "R. L.",
                    "initial": "R.L.",
                    "last": "Korn"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Fisher"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Jeevanandam"
                },
                {
                    "first": "V. P.",
                    "initial": "V.P.",
                    "last": "Addonizio"
                }
            ],
            "firstpage": "97",
            "issn": "00221058",
            "lastpage": "102",
            "pmid": "10148074",
            "pub_year": 1992,
            "title": "The effects of heparin bound surface modification (Carmeda\u00ae Bioactive Surface) on human platelet alterations during simulated extracorporeal circulation",
            "volume": "24"
        },
        "bb0320": {
            "authors": [
                {
                    "first": "R. L.",
                    "initial": "R.L.",
                    "last": "Korn"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Fisher"
                },
                {
                    "first": "E. R.",
                    "initial": "E.R.",
                    "last": "Livingston"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Stenach"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Fishman"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Jeevanandam"
                },
                {
                    "first": "V. P.",
                    "initial": "V.P.",
                    "last": "Addonizio"
                }
            ],
            "doi": "10.1016/S0022-5223(96)70384-7",
            "firstpage": "1073",
            "issn": "00225223",
            "lastpage": "1084",
            "pmid": "8622305",
            "pub_year": 1996,
            "title": "The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation",
            "volume": "111"
        },
        "bb0325": {
            "authors": [
                {
                    "first": "H. P.",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Heller"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Gallimore"
                },
                {
                    "first": "H. E.",
                    "initial": "H.E.",
                    "last": "Hoffmeister"
                }
            ],
            "doi": "10.1097/00001721-199410000-00001",
            "firstpage": "673",
            "issn": "09575235",
            "lastpage": "678",
            "pmid": "7865672",
            "pub_year": 1994,
            "title": "Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model",
            "volume": "5"
        },
        "bb0330": {
            "authors": [
                {
                    "first": "Hans Peter",
                    "initial": "H.P.",
                    "last": "Wendel"
                },
                {
                    "first": "Hans Joachim",
                    "initial": "H.J.",
                    "last": "Schulze"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Heller"
                },
                {
                    "first": "Hans Martin",
                    "initial": "H.M.",
                    "last": "Hoffmeister"
                }
            ],
            "doi": "10.1016/S1053-0770(99)90208-2",
            "firstpage": "388",
            "issn": "10530770",
            "lastpage": "392",
            "pmid": "10468249",
            "pub_year": 1999,
            "title": "Platelet protection in coronary artery surgery: Benefits of heparin- coated circuits and high-dose aprotinin therapy",
            "volume": "13"
        },
        "bb0335": {
            "authors": [
                {
                    "first": "Cunji",
                    "initial": "C.",
                    "last": "Gao"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Boylan"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Fang"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Wilcox"
                },
                {
                    "first": "Debra K.",
                    "initial": "D.K.",
                    "last": "Newman"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Newman"
                }
            ],
            "doi": "10.1182/blood-2010-09-307751",
            "firstpage": "4946",
            "issn": "00064971",
            "lastpage": "4952",
            "pmid": "21368290",
            "pub_year": 2011,
            "title": "Heparin promotes platelet responsiveness by potentiating \u03b1IIb\u03b23-mediated outside-in signaling",
            "volume": "117"
        },
        "bb0340": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Elgue"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Olsson"
                }
            ],
            "doi": "10.1002/jbm.820290513",
            "firstpage": "655",
            "issn": "00219304",
            "lastpage": "661",
            "pmid": "7622551",
            "pub_year": 1995,
            "title": "Control of contact activation on end\u2010point immobilized heparin: The role of antithrombin and the specific antithrombin\u2010binding sequence",
            "volume": "29"
        },
        "bb0345": {
            "authors": [
                {
                    "first": "Eva M.",
                    "initial": "E.M.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Linhardt"
                }
            ],
            "doi": "10.1161/01.ATV.0000137189.22999.3f",
            "firstpage": "1549",
            "issn": "10795642",
            "lastpage": "1557",
            "pmid": "15231514",
            "pub_year": 2004,
            "title": "Heparin-binding domains in vascular biology",
            "volume": "24"
        },
        "bb0350": {
            "authors": [
                {
                    "first": "Ishan",
                    "initial": "I.",
                    "last": "Capila"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Linhardt"
                }
            ],
            "doi": "10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B",
            "firstpage": "390",
            "issn": "14337851",
            "lastpage": "412",
            "pmid": "12491369",
            "pub_year": 2002,
            "title": "Heparin - Protein interactions",
            "volume": "41"
        },
        "bb0355": {
            "authors": [
                {
                    "first": "Maurice",
                    "initial": "M.",
                    "last": "Petitou"
                },
                {
                    "first": "Benito",
                    "initial": "B.",
                    "last": "Casu"
                },
                {
                    "first": "Ulf",
                    "initial": "U.",
                    "last": "Lindahl"
                }
            ],
            "doi": "10.1016/S0300-9084(03)00078-6",
            "firstpage": "83",
            "issn": "03009084",
            "lastpage": "89",
            "pmid": "12765778",
            "pub_year": 2003,
            "title": "1976-1983, a critical period in the history of heparin: The discovery of the antithrombin binding site",
            "volume": "85"
        },
        "bb0360": null,
        "bb0365": null,
        "bb0370": null,
        "bb0375": {
            "authors": [
                {
                    "first": "Kalervo",
                    "initial": "K.",
                    "last": "Werkkala"
                },
                {
                    "first": "Janne J.",
                    "initial": "J.J.",
                    "last": "Jokinen"
                },
                {
                    "first": "Leena",
                    "initial": "L.",
                    "last": "Soininen"
                },
                {
                    "first": "G\u00f6ran",
                    "initial": "G.",
                    "last": "Dellgren"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Hallhagen"
                },
                {
                    "first": "Fredrik",
                    "initial": "F.",
                    "last": "Sundberg"
                },
                {
                    "first": "Jonas",
                    "initial": "J.",
                    "last": "Andersson"
                },
                {
                    "first": "Lars I.",
                    "initial": "L.I.",
                    "last": "Dahms"
                },
                {
                    "first": "Nadine",
                    "initial": "N.",
                    "last": "Jurrmann"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Ersel"
                }
            ],
            "doi": "10.1097/MAT.0000000000000314",
            "firstpage": "139",
            "issn": "10582916",
            "lastpage": "142",
            "pmid": "26579977",
            "pub_year": 2016,
            "title": "Clinical durability of the CARMEDA bioactive surface in EXCOR ventricular assist device pumps",
            "volume": "62"
        },
        "bb0380": null,
        "bb0385": {
            "authors": [
                {
                    "first": "Bader E.",
                    "initial": "B.E.",
                    "last": "Hussaini"
                },
                {
                    "first": "Patrick R.",
                    "initial": "P.R.",
                    "last": "Treanor"
                },
                {
                    "first": "Nancy A.",
                    "initial": "N.A.",
                    "last": "Healey"
                },
                {
                    "first": "Xiu Gui",
                    "initial": "X.G.",
                    "last": "Lu"
                },
                {
                    "first": "Shukri F.",
                    "initial": "S.F.",
                    "last": "Khuri"
                },
                {
                    "first": "Hemant S.",
                    "initial": "H.S.",
                    "last": "Thatte"
                }
            ],
            "doi": "10.1016/j.jss.2010.01.037",
            "firstpage": "e7",
            "issn": "00224804",
            "pub_year": 2011,
            "title": "Multifactorial comparison of modified and conventional perfusion strategies in a porcine model of cardiopulmonary bypass",
            "volume": "168"
        },
        "bb0390": {
            "authors": [
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Nilsson"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Storm"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Thelin"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bagge"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hultman"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Thorelius"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Nilsson"
                }
            ],
            "doi": "10.1111/j.1525-1594.1990.tb01591.x",
            "firstpage": "46",
            "issn": "0160564X",
            "lastpage": "48",
            "pmid": "2302076",
            "pub_year": 1990,
            "title": "Heparin\u2010Coated Equipment Reduces Complement Activation during Cardiopulmonary Bypass in the Pig",
            "volume": "14"
        },
        "bb0395": {
            "authors": [
                {
                    "first": "Masaaki",
                    "initial": "M.",
                    "last": "Fukutomi"
                },
                {
                    "first": "Shuichi",
                    "initial": "S.",
                    "last": "Kobayashi"
                },
                {
                    "first": "Kazuo",
                    "initial": "K.",
                    "last": "Niwaya"
                },
                {
                    "first": "Yoshihiro",
                    "initial": "Y.",
                    "last": "Hamada"
                },
                {
                    "first": "Soichiro",
                    "initial": "S.",
                    "last": "Kitamura"
                }
            ],
            "doi": "10.1111/j.1525-1594.1996.tb04538.x",
            "firstpage": "767",
            "issn": "0160564X",
            "lastpage": "776",
            "pmid": "8828766",
            "pub_year": 1996,
            "title": "Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment",
            "volume": "20"
        },
        "bb0400": {
            "authors": [
                {
                    "first": "T. E.",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Videm"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Riesenfeld"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Garred"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Svennevig"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Fosse"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Hogasen"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Harboe"
                }
            ],
            "doi": "10.1111/j.1365-2249.1991.tb06202.x",
            "firstpage": "21",
            "issn": "00099104",
            "lastpage": "26",
            "pmid": "1934602",
            "pub_year": 1991,
            "title": "COMPLEMENT ACTIVATION AND BIOINCOMPATIBIUTY: The terminal complement complex for evaluation and surface modification with heparin for Improvement of biomaterials",
            "volume": "86"
        },
        "bb0405": {
            "authors": [
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Videm"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Svennevig"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Fosse"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Semb"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Osterud"
                },
                {
                    "first": "T. E.",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Nielsen"
                }
            ],
            "doi": "10.1016/s0022-5223(19)34966-9",
            "firstpage": "806",
            "issn": "00225223",
            "lastpage": "813",
            "pmid": "1548925",
            "pub_year": 1992,
            "title": "Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations",
            "volume": "103"
        },
        "bb0410": {
            "authors": [
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Fosse"
                },
                {
                    "first": "Oddvar",
                    "initial": "O.",
                    "last": "Moen"
                },
                {
                    "first": "Egil",
                    "initial": "E.",
                    "last": "Johnson"
                },
                {
                    "first": "Gudmund",
                    "initial": "G.",
                    "last": "Semb"
                },
                {
                    "first": "Vibeke",
                    "initial": "V.",
                    "last": "Brockmeier"
                },
                {
                    "first": "Tom Eirik",
                    "initial": "T.E.",
                    "last": "Mollnes"
                },
                {
                    "first": "Magne K.",
                    "initial": "M.K.",
                    "last": "Fagerhol"
                },
                {
                    "first": "Per",
                    "initial": "P.",
                    "last": "Venge"
                }
            ],
            "doi": "10.1016/0003-4975(94)92231-4",
            "firstpage": "472",
            "issn": "00034975",
            "lastpage": "477",
            "pmid": "8067851",
            "pub_year": 1994,
            "title": "Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass",
            "volume": "58"
        },
        "bb0415": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Mottaghy"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Oedekoven"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Poppel"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Kovacs"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kirschfink"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Bruchmuller"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kashefi"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Geisen"
                }
            ],
            "doi": "10.1177/039139889101401108",
            "firstpage": "721",
            "issn": "03913988",
            "lastpage": "728",
            "pmid": "1757160",
            "pub_year": 1991,
            "title": "Heparin-coated versus noncoated surfaces for extracorporeal circulation",
            "volume": "14"
        },
        "bb0420": {
            "authors": [
                {
                    "first": "Bansi",
                    "initial": "B.",
                    "last": "Koul"
                },
                {
                    "first": "Ole",
                    "initial": "O.",
                    "last": "Vesterqvist"
                },
                {
                    "first": "Nils",
                    "initial": "N.",
                    "last": "Egberg"
                },
                {
                    "first": "Stig",
                    "initial": "S.",
                    "last": "Steen"
                }
            ],
            "doi": "10.1016/0003-4975(92)90386-I",
            "firstpage": "1046",
            "issn": "00034975",
            "lastpage": "1051",
            "pmid": "1596127",
            "pub_year": 1992,
            "title": "Twenty-four-hour heparin-free veno-right ventricular ECMO: An experimental study",
            "volume": "53"
        },
        "bb0425": {
            "authors": [
                {
                    "first": "Frans B.",
                    "initial": "F.B.",
                    "last": "Pl\u00f6tz"
                },
                {
                    "first": "Willem",
                    "initial": "W.",
                    "last": "van Oeveren"
                },
                {
                    "first": "Karl A.",
                    "initial": "K.A.",
                    "last": "Hultquist"
                },
                {
                    "first": "Cathie",
                    "initial": "C.",
                    "last": "Miller"
                },
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Bartlett"
                },
                {
                    "first": "Charles R.H.",
                    "initial": "C.R.H.",
                    "last": "Wildevuur"
                }
            ],
            "doi": "10.1111/j.1525-1594.1992.tb00533.x",
            "firstpage": "366",
            "issn": "0160564X",
            "lastpage": "370",
            "pmid": "10078276",
            "pub_year": 1992,
            "title": "A Heparin\u2010Coated Circuit Reduces Complement Activation and the Release of Leukocyte Inflammatory Mediators During Extracorporeal Circulation in a Rabbit",
            "volume": "16"
        },
        "bb0430": {
            "authors": [
                {
                    "first": "Chris Brown",
                    "initial": "C.B.",
                    "last": "Mahoney"
                },
                {
                    "first": "Gerald M.",
                    "initial": "G.M.",
                    "last": "Lemole"
                }
            ],
            "doi": "10.1016/S1010-7940(99)00157-8",
            "firstpage": "206",
            "issn": "10107940",
            "lastpage": "210",
            "pmid": "10485422",
            "pub_year": 1999,
            "title": "Transfusion after coronary artery bypass surgery: The impact of heparin-bonded circuits",
            "volume": "16"
        },
        "bb0435": {
            "authors": [
                {
                    "first": "Alfred H.",
                    "initial": "A.H.",
                    "last": "Stammers"
                }
            ],
            "doi": "10.1053/jcan.2001.26521",
            "firstpage": "539",
            "issn": "10530770",
            "lastpage": "541",
            "pub_year": 2001,
            "title": "Biocompatibility of trillium biopassive surface-coated oxygenator during cardiopulmonary bypass",
            "volume": "15"
        },
        "bb0440": {
            "authors": [
                {
                    "first": "Alfred H.",
                    "initial": "A.H.",
                    "last": "Stammers"
                },
                {
                    "first": "Kevin A.",
                    "initial": "K.A.",
                    "last": "Christensen"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Lynch"
                },
                {
                    "first": "Douglas P.",
                    "initial": "D.P.",
                    "last": "Zavadil"
                },
                {
                    "first": "Joseph J.",
                    "initial": "J.J.",
                    "last": "Deptula"
                },
                {
                    "first": "R. Troy",
                    "initial": "R.T.",
                    "last": "Sydzyik"
                }
            ],
            "firstpage": "135",
            "issn": "00221058",
            "lastpage": "141",
            "pmid": "10847956",
            "pub_year": 1999,
            "title": "Quantitative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass",
            "volume": "31"
        },
        "bb0445": {
            "authors": [
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Mahmood"
                },
                {
                    "first": "Haris",
                    "initial": "H.",
                    "last": "Bilal"
                },
                {
                    "first": "Mahvash",
                    "initial": "M.",
                    "last": "Zaman"
                },
                {
                    "first": "Augustine",
                    "initial": "A.",
                    "last": "Tang"
                }
            ],
            "doi": "10.1093/icvts/ivr124",
            "firstpage": "406",
            "issn": "15699293",
            "lastpage": "414",
            "pmid": "22228288",
            "pub_year": 2012,
            "title": "Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?",
            "volume": "14"
        },
        "bb0450": {
            "authors": [
                {
                    "first": "C. Brown",
                    "initial": "C.B.",
                    "last": "Mahoney"
                }
            ],
            "doi": "10.1177/026765919801300307",
            "firstpage": "192",
            "issn": "02676591",
            "lastpage": "204",
            "pmid": "9638717",
            "pub_year": 1998,
            "title": "Heparin-bonded circuits: Clinical outcomes and costs",
            "volume": "13"
        },
        "bb0455": null,
        "bb0460": {
            "authors": [
                {
                    "first": "Michel E.",
                    "initial": "M.E.",
                    "last": "Bertrand"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Legrand"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Boland"
                },
                {
                    "first": "Eckart",
                    "initial": "E.",
                    "last": "Fleck"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Bonnier"
                },
                {
                    "first": "Hakan",
                    "initial": "H.",
                    "last": "Emmanuelson"
                },
                {
                    "first": "Matty",
                    "initial": "M.",
                    "last": "Vrolix"
                },
                {
                    "first": "Luc",
                    "initial": "L.",
                    "last": "Missault"
                },
                {
                    "first": "Sergio",
                    "initial": "S.",
                    "last": "Chierchia"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Casaccia"
                },
                {
                    "first": "Luigi",
                    "initial": "L.",
                    "last": "Niccoli"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Oto"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "White"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Webb-Peploe"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Van Belle"
                },
                {
                    "first": "Eug\u00e8ne P.",
                    "initial": "E.P.",
                    "last": "McFadden"
                }
            ],
            "doi": "10.1161/01.CIR.98.16.1597",
            "firstpage": "1597",
            "issn": "00097322",
            "lastpage": "1603",
            "pmid": "9778323",
            "pub_year": 1998,
            "title": "Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study",
            "volume": "98"
        },
        "bb0465": {
            "authors": [
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Colombo"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Hall"
                },
                {
                    "first": "Shigeru",
                    "initial": "S.",
                    "last": "Nakamura"
                },
                {
                    "first": "Yaron",
                    "initial": "Y.",
                    "last": "Almagor"
                },
                {
                    "first": "Luigi",
                    "initial": "L.",
                    "last": "Maiello"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Martini"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Gaglione"
                },
                {
                    "first": "Steven L.",
                    "initial": "S.L.",
                    "last": "Goldberg"
                },
                {
                    "first": "Jonathan M.",
                    "initial": "J.M.",
                    "last": "Tobis"
                }
            ],
            "doi": "10.1161/01.CIR.91.6.1676",
            "firstpage": "1676",
            "issn": "00097322",
            "lastpage": "1688",
            "pmid": "7882474",
            "pub_year": 1995,
            "title": "Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance",
            "volume": "91"
        },
        "bb0470": {
            "authors": [
                {
                    "first": "Ga\u00ebtan J.",
                    "initial": "G.J.",
                    "last": "Karrillon"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Morice"
                },
                {
                    "first": "Edgar",
                    "initial": "E.",
                    "last": "Benveniste"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Bunouf"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Aubry"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cattan"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Chevalier"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Commeau"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Cribier"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Eiferman"
                },
                {
                    "first": "Gilles",
                    "initial": "G.",
                    "last": "Grollier"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Guerin"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Henry"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Lefevre"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Livarek"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Louvard"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Marco"
                },
                {
                    "first": "Serge",
                    "initial": "S.",
                    "last": "Makowski"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Monassier"
                },
                {
                    "first": "Jean Marc",
                    "initial": "J.M.",
                    "last": "Pernes"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Rioux"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Spaulding"
                },
                {
                    "first": "Gilles",
                    "initial": "G.",
                    "last": "Zemour"
                }
            ],
            "doi": "10.1161/01.CIR.94.7.1519",
            "firstpage": "1519",
            "issn": "00097322",
            "lastpage": "1527",
            "pmid": "8840839",
            "pub_year": 1996,
            "title": "Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French multicenter registry",
            "volume": "94"
        },
        "bb0475": {
            "authors": [
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Sch\u00f6mig"
                },
                {
                    "first": "Franz Josef",
                    "initial": "F.J.",
                    "last": "Neumann"
                },
                {
                    "first": "Adnan",
                    "initial": "A.",
                    "last": "Kastrati"
                },
                {
                    "first": "Helmut",
                    "initial": "H.",
                    "last": "Sch\u00fchlen"
                },
                {
                    "first": "Rudolf",
                    "initial": "R.",
                    "last": "Blasini"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Hadamitzky"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Walter"
                },
                {
                    "first": "Eva Maria",
                    "initial": "E.M.",
                    "last": "Zitzmann-Roth"
                },
                {
                    "first": "Gert",
                    "initial": "G.",
                    "last": "Richardt"
                },
                {
                    "first": "Eckhard",
                    "initial": "E.",
                    "last": "Alt"
                },
                {
                    "first": "Claus",
                    "initial": "C.",
                    "last": "Schmitt"
                },
                {
                    "first": "Kurt",
                    "initial": "K.",
                    "last": "Ulm"
                }
            ],
            "doi": "10.1056/NEJM199604253341702",
            "firstpage": "1084",
            "issn": "00284793",
            "lastpage": "1089",
            "pmid": "8598866",
            "pub_year": 1996,
            "title": "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents",
            "volume": "334"
        },
        "bb0480": {
            "authors": [
                {
                    "first": "Vishal",
                    "initial": "V.",
                    "last": "Gupta"
                },
                {
                    "first": "Bhooma R.",
                    "initial": "B.R.",
                    "last": "Aravamuthan"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Baskerville"
                },
                {
                    "first": "Susan K.",
                    "initial": "S.K.",
                    "last": "Smith"
                },
                {
                    "first": "Vijaya",
                    "initial": "V.",
                    "last": "Gupta"
                },
                {
                    "first": "Michael A.",
                    "initial": "M.A.",
                    "last": "Lauer"
                },
                {
                    "first": "Tim A.",
                    "initial": "T.A.",
                    "last": "Fischell"
                }
            ],
            "firstpage": "304",
            "issn": "10423931",
            "lastpage": "310",
            "pmid": "15155999",
            "pub_year": 2004,
            "title": "Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, \"real world\" registry",
            "volume": "16"
        },
        "bb0485": {
            "authors": [
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Hardhammar"
                },
                {
                    "first": "H. M.M.",
                    "initial": "H.M.M.",
                    "last": "Van Beusekom"
                },
                {
                    "first": "H. U.",
                    "initial": "H.U.",
                    "last": "Emanuelsson"
                },
                {
                    "first": "S. H.",
                    "initial": "S.H.",
                    "last": "Hofma"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Albertsson"
                },
                {
                    "first": "P. D.",
                    "initial": "P.D.",
                    "last": "Verdouw"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Boersma"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Serruys"
                },
                {
                    "first": "W. J.",
                    "initial": "W.J.",
                    "last": "Van der Giessen"
                }
            ],
            "doi": "10.1161/01.CIR.93.3.423",
            "firstpage": "423",
            "issn": "00097322",
            "lastpage": "430",
            "pmid": "8565158",
            "pub_year": 1996,
            "title": "Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries",
            "volume": "93"
        },
        "bb0490": null,
        "bb0495": null,
        "bb0500": null,
        "bb0505": {
            "authors": [
                {
                    "first": "Peter H.",
                    "initial": "P.H.",
                    "last": "Lin"
                },
                {
                    "first": "Nicolas A.",
                    "initial": "N.A.",
                    "last": "Chronos"
                },
                {
                    "first": "Monique M.",
                    "initial": "M.M.",
                    "last": "Marijianowski"
                },
                {
                    "first": "Changyi",
                    "initial": "C.",
                    "last": "Chen"
                },
                {
                    "first": "Ruth L.",
                    "initial": "R.L.",
                    "last": "Bush"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Conklin"
                },
                {
                    "first": "Alan B.",
                    "initial": "A.B.",
                    "last": "Lumsden"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Hanson"
                }
            ],
            "doi": "10.1097/01.RVI.0000071088.76348.23",
            "firstpage": "603",
            "issn": "10510443",
            "lastpage": "611",
            "pmid": "12761314",
            "pub_year": 2003,
            "title": "Heparin-coated balloon-expandable stent reduces intimal hyperplasia in the iliac artery in baboons",
            "volume": "14"
        },
        "bb0510": {
            "authors": [
                {
                    "first": "Peter H.",
                    "initial": "P.H.",
                    "last": "Lin"
                },
                {
                    "first": "Nicolas A.",
                    "initial": "N.A.",
                    "last": "Chronos"
                },
                {
                    "first": "Monique M.",
                    "initial": "M.M.",
                    "last": "Marijianowski"
                },
                {
                    "first": "Changyi",
                    "initial": "C.",
                    "last": "Chen"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Conklin"
                },
                {
                    "first": "Ruth L.",
                    "initial": "R.L.",
                    "last": "Bush"
                },
                {
                    "first": "Alan B.",
                    "initial": "A.B.",
                    "last": "Lumsden"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Hanson"
                }
            ],
            "doi": "10.1016/S0022-4804(03)00124-0",
            "firstpage": "84",
            "issn": "00224804",
            "lastpage": "90",
            "pmid": "12873438",
            "pub_year": 2003,
            "title": "Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model",
            "volume": "112"
        },
        "bb0515": {
            "authors": [
                {
                    "first": "Roxana",
                    "initial": "R.",
                    "last": "Mehran"
                },
                {
                    "first": "Eugenia",
                    "initial": "E.",
                    "last": "Nikolsky"
                },
                {
                    "first": "Edoardo",
                    "initial": "E.",
                    "last": "Camenzind"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Zelizko"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kranjec"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "Seabra-Gomes"
                },
                {
                    "first": "Manuela",
                    "initial": "M.",
                    "last": "Negoita"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Slack"
                },
                {
                    "first": "Chaim",
                    "initial": "C.",
                    "last": "Lotan"
                }
            ],
            "doi": "10.1016/j.ahj.2005.01.027",
            "firstpage": "1171",
            "issn": "00028703",
            "lastpage": "1176",
            "pmid": "16338254",
            "pub_year": 2005,
            "title": "An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation",
            "volume": "150"
        },
        "bb0520": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "W\u00f6hrle"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Al-Khayer"
                },
                {
                    "first": "U.",
                    "initial": "U.",
                    "last": "Gr\u00f6tzinger"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Schindler"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kochs"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Hombach"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "H\u00f6her"
                }
            ],
            "doi": "10.1053/euhj.2001.2608",
            "firstpage": "1808",
            "issn": "0195668X",
            "lastpage": "1816",
            "pmid": "11549303",
            "pub_year": 2001,
            "title": "Comparison of the heparin coated vs the uncoated Jostent\u00ae - No influence on restenosis or clinical outcome",
            "volume": "22"
        },
        "bb0525": {
            "authors": [
                {
                    "first": "Matty C.M.",
                    "initial": "M.C.M.",
                    "last": "Vrolix"
                },
                {
                    "first": "Victor M.",
                    "initial": "V.M.",
                    "last": "Legrand"
                },
                {
                    "first": "Johan H.C.",
                    "initial": "J.H.C.",
                    "last": "Reiber"
                },
                {
                    "first": "Gille",
                    "initial": "G.",
                    "last": "Grollier"
                },
                {
                    "first": "Martin J.",
                    "initial": "M.J.",
                    "last": "Schalij"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Brunel"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Martinez-Elbal"
                },
                {
                    "first": "Manuel",
                    "initial": "M.",
                    "last": "Gomez-Recio"
                },
                {
                    "first": "Frits W.H.M.",
                    "initial": "F.W.H.M.",
                    "last": "B\u00e4r"
                },
                {
                    "first": "Michel E.",
                    "initial": "M.E.",
                    "last": "Bertrand"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Colombo"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Brachman"
                }
            ],
            "doi": "10.1016/S0002-9149(00)00951-6",
            "firstpage": "385",
            "issn": "00029149",
            "lastpage": "389",
            "pmid": "10946029",
            "pub_year": 2000,
            "title": "Heparin-coated Wiktor stents in human coronary arteries (MENTOR Trial)",
            "volume": "86"
        },
        "bb0530": {
            "authors": [
                {
                    "first": "Ender",
                    "initial": "E.",
                    "last": "Semiz"
                },
                {
                    "first": "Cengiz",
                    "initial": "C.",
                    "last": "Ermi\u015f"
                },
                {
                    "first": "Selim",
                    "initial": "S.",
                    "last": "Yal\u00e7inkaya"
                },
                {
                    "first": "Oktay",
                    "initial": "O.",
                    "last": "Sancaktar"
                },
                {
                    "first": "Necmi",
                    "initial": "N.",
                    "last": "De\u01e7er"
                }
            ],
            "doi": "10.1536/jhj.44.889",
            "firstpage": "889",
            "issn": "00214868",
            "lastpage": "898",
            "pmid": "14711184",
            "pub_year": 2003,
            "title": "Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent",
            "volume": "44"
        },
        "bb0535": {
            "authors": [
                {
                    "first": "Olivier F.",
                    "initial": "O.F.",
                    "last": "Bertrand"
                },
                {
                    "first": "Rajender",
                    "initial": "R.",
                    "last": "Sipehia"
                },
                {
                    "first": "Rosaire",
                    "initial": "R.",
                    "last": "Mongrain"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Rod\u00e9s"
                },
                {
                    "first": "Jean Claude",
                    "initial": "J.C.",
                    "last": "Tardif"
                },
                {
                    "first": "Luc",
                    "initial": "L.",
                    "last": "Bilodeau"
                },
                {
                    "first": "Gilles",
                    "initial": "G.",
                    "last": "C\u00f4t\u00e9"
                },
                {
                    "first": "Martial G.",
                    "initial": "M.G.",
                    "last": "Bourassa"
                }
            ],
            "doi": "10.1016/S0735-1097(98)00289-7",
            "firstpage": "562",
            "issn": "07351097",
            "lastpage": "571",
            "pmid": "9741494",
            "pub_year": 1998,
            "title": "Biocompatibility aspects of new stent technology",
            "volume": "32"
        },
        "bb0540": null,
        "bb0545": {
            "authors": [
                {
                    "first": "Peter H.",
                    "initial": "P.H.",
                    "last": "Lin"
                },
                {
                    "first": "Ruth L.",
                    "initial": "R.L.",
                    "last": "Bush"
                },
                {
                    "first": "Qizhi",
                    "initial": "Q.",
                    "last": "Yao"
                },
                {
                    "first": "Alan B.",
                    "initial": "A.B.",
                    "last": "Lumsden"
                },
                {
                    "first": "Changyi",
                    "initial": "C.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.jss.2003.12.026",
            "firstpage": "45",
            "issn": "00224804",
            "lastpage": "52",
            "pmid": "15093716",
            "pub_year": 2004,
            "title": "Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model",
            "volume": "118"
        },
        "bb0550": {
            "authors": [
                {
                    "first": "Peter H.",
                    "initial": "P.H.",
                    "last": "Lin"
                },
                {
                    "first": "Changyi",
                    "initial": "C.",
                    "last": "Chen"
                },
                {
                    "first": "Ruth L.",
                    "initial": "R.L.",
                    "last": "Bush"
                },
                {
                    "first": "Qizhi",
                    "initial": "Q.",
                    "last": "Yao"
                },
                {
                    "first": "Alan B.",
                    "initial": "A.B.",
                    "last": "Lumsden"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Hanson"
                }
            ],
            "doi": "10.1016/j.jvs.2004.01.046",
            "firstpage": "1322",
            "issn": "07415214",
            "lastpage": "1328",
            "pmid": "15192575",
            "pub_year": 2004,
            "title": "Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model",
            "volume": "39"
        },
        "bb0555": {
            "authors": [
                {
                    "first": "J. S.",
                    "initial": "J.S.",
                    "last": "Lindholt"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Gottschalksen"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Johannesen"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Dueholm"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Ravn"
                },
                {
                    "first": "E. D.",
                    "initial": "E.D.",
                    "last": "Christensen"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Viddal"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Fl\u00f8renes"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Pedersen"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Rasmussen"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Carstensen"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Gr\u00f8ndal"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Fasting"
                }
            ],
            "doi": "10.1016/j.ejvs.2011.01.021",
            "firstpage": "668",
            "issn": "10785884",
            "lastpage": "673",
            "pmid": "21376643",
            "pub_year": 2011,
            "title": "The Scandinavian Propaten\u00ae Trial - 1-Year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses - A randomised clinical controlled multi-centre trial",
            "volume": "41"
        },
        "bb0560": {
            "authors": [
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Daenens"
                },
                {
                    "first": "Stijn",
                    "initial": "S.",
                    "last": "Schepers"
                },
                {
                    "first": "Inge",
                    "initial": "I.",
                    "last": "Fourneau"
                },
                {
                    "first": "Sabrina",
                    "initial": "S.",
                    "last": "Houthoofd"
                },
                {
                    "first": "Andr\u00e9",
                    "initial": "A.",
                    "last": "Nevelsteen"
                }
            ],
            "doi": "10.1016/j.jvs.2008.12.009",
            "firstpage": "1210",
            "issn": "07415214",
            "lastpage": "1216",
            "pmid": "19394550",
            "pub_year": 2009,
            "title": "Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses: 1- and 2-year results",
            "volume": "49"
        },
        "bb0565": null,
        "bb0570": {
            "authors": [
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Greinacher"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Kohlmann"
                },
                {
                    "first": "Ulrike",
                    "initial": "U.",
                    "last": "Strobel"
                },
                {
                    "first": "Jo Ann I.",
                    "initial": "J.A.I.",
                    "last": "Sheppard"
                },
                {
                    "first": "Theodore E.",
                    "initial": "T.E.",
                    "last": "Warkentin"
                }
            ],
            "doi": "10.1182/blood-2008-08-173062",
            "firstpage": "4970",
            "issn": "00064971",
            "lastpage": "4976",
            "pmid": "19109231",
            "pub_year": 2009,
            "title": "The temporal profile of the anti-PF4/heparin immune response",
            "volume": "113"
        },
        "bb0575": {
            "authors": [
                {
                    "first": "T. E.",
                    "initial": "T.E.",
                    "last": "Warkentin"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Kelton"
                }
            ],
            "doi": "10.1056/NEJM200104263441704",
            "firstpage": "1286",
            "issn": "00284793",
            "lastpage": "1292",
            "pmid": "11320387",
            "pub_year": 2001,
            "title": "Temporal aspects of heparin-induced thrombocytopenia",
            "volume": "344"
        },
        "bb0580": {
            "authors": [
                {
                    "first": "Norbert",
                    "initial": "N.",
                    "last": "Lubenow"
                },
                {
                    "first": "Reiner",
                    "initial": "R.",
                    "last": "Kempf"
                },
                {
                    "first": "Angelika",
                    "initial": "A.",
                    "last": "Eichner"
                },
                {
                    "first": "Petra",
                    "initial": "P.",
                    "last": "Eichler"
                },
                {
                    "first": "Lena E.",
                    "initial": "L.E.",
                    "last": "Carlsson"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Greinacher"
                }
            ],
            "doi": "10.1378/chest.122.1.37",
            "firstpage": "37",
            "issn": "00123692",
            "lastpage": "42",
            "pmid": "12114336",
            "pub_year": 2002,
            "title": "Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin",
            "volume": "122"
        },
        "bb0585": null,
        "bb0590": {
            "authors": [
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Koster"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Loebe"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Sodian"
                },
                {
                    "first": "Evgenij V.",
                    "initial": "E.V.",
                    "last": "Potapov"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Hansen"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "M\u00fcller"
                },
                {
                    "first": "Fritz",
                    "initial": "F.",
                    "last": "Mertzlufft"
                },
                {
                    "first": "George J.",
                    "initial": "G.J.",
                    "last": "Crystal"
                },
                {
                    "first": "Herrmann",
                    "initial": "H.",
                    "last": "Kuppe"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Hetzer"
                }
            ],
            "doi": "10.1067/mtc.2001.111655",
            "firstpage": "331",
            "issn": "00225223",
            "lastpage": "335",
            "pub_year": 2001,
            "title": "Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices",
            "volume": "121"
        },
        "bb0595": {
            "authors": [
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Koster"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "S\u00e4nger"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Hansen"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Sodian"
                },
                {
                    "first": "Fritz",
                    "initial": "F.",
                    "last": "Mertzlufft"
                },
                {
                    "first": "Cornelia",
                    "initial": "C.",
                    "last": "Harke"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Kuppe"
                },
                {
                    "first": "Roland",
                    "initial": "R.",
                    "last": "Hetzer"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Loebe"
                }
            ],
            "doi": "10.1097/00002480-200005000-00015",
            "firstpage": "319",
            "issn": "10582916",
            "lastpage": "322",
            "pmid": "10826744",
            "pub_year": 2000,
            "title": "Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices",
            "volume": "46"
        },
        "bb0600": {
            "authors": [
                {
                    "first": "Subhash",
                    "initial": "S.",
                    "last": "Thakur"
                },
                {
                    "first": "John P.",
                    "initial": "J.P.",
                    "last": "Pigott"
                },
                {
                    "first": "Anthony J.",
                    "initial": "A.J.",
                    "last": "Comerota"
                }
            ],
            "doi": "10.1016/j.jvs.2008.12.004",
            "firstpage": "1037",
            "issn": "07415214",
            "lastpage": "1040",
            "pmid": "19341891",
            "pub_year": 2009,
            "title": "Heparin-induced thrombocytopenia after implantation of a heparin-bonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management",
            "volume": "49"
        },
        "bb0605": {
            "authors": [
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Gabrielli"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Siani"
                },
                {
                    "first": "Maria Sofia",
                    "initial": "M.S.",
                    "last": "Rosati"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Antonelli"
                },
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Accrocca"
                },
                {
                    "first": "Gioacchino Alessandro",
                    "initial": "G.A.",
                    "last": "Giordano"
                },
                {
                    "first": "Giustino",
                    "initial": "G.",
                    "last": "Marcucci"
                }
            ],
            "doi": "10.1016/j.avsg.2010.12.040",
            "firstpage": "840",
            "issn": "08905096",
            "lastpage": "840.e12",
            "pub_year": 2011,
            "title": "Heparin-induced thrombocytopenia type II because of heparin-coated polytetrafluoroethylene graft used to bypass",
            "volume": "25"
        },
        "bb0610": {
            "authors": [
                {
                    "first": "M. D.",
                    "initial": "M.D.",
                    "last": "Wheatcroft"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Greco"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Tse"
                },
                {
                    "first": "Graham",
                    "initial": "G.",
                    "last": "Roche-Nagle"
                }
            ],
            "doi": "10.1258/vasc.2011.cr0280",
            "firstpage": "338",
            "issn": "17085381",
            "lastpage": "341",
            "pmid": "22008977",
            "pub_year": 2011,
            "title": "Heparin-induced thrombocytopenia in the presence of a heparin-bonded bypass graft",
            "volume": "19"
        },
        "bb0615": {
            "authors": [
                {
                    "first": "T. E.",
                    "initial": "T.E.",
                    "last": "Warkentin"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Kelton"
                }
            ],
            "doi": "10.7326/0003-4819-135-7-200110020-00009",
            "firstpage": "502",
            "issn": "00034819",
            "lastpage": "506",
            "pmid": "11578153",
            "pub_year": 2001,
            "title": "Delayed-onset heparin-induced thrombocytopenia and thrombosis",
            "volume": "135"
        },
        "bb0620": null
    },
    "body_text": [
        {
            "endOffset": 47344,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0335": {
                    "endOffset": 47343,
                    "startOffset": 47339
                }
            },
            "secId": "s0085",
            "sentence": "It is however interesting that in its freely soluble state, heparin has mild platelet stimulating properties [67].",
            "startOffset": 47230,
            "title": "Reduced platelet adherence and activation"
        },
        {
            "endOffset": 37665,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0035",
            "sentence": "Since 2005, Corline began to expand the application of their heparin technology beyond medical devices.",
            "startOffset": 37562,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 40329,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "This heparin bonding technology was developed by Carmeda AB, a wholly owned subsidiary of W.L. Gore & Associates, Inc.",
            "startOffset": 40211,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 60045,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0190": {
                    "endOffset": 60044,
                    "startOffset": 60032
                },
                "bb0520": {
                    "endOffset": 60044,
                    "startOffset": 60032
                },
                "bb0525": {
                    "endOffset": 60044,
                    "startOffset": 60032
                },
                "bb0530": {
                    "endOffset": 60044,
                    "startOffset": 60032
                },
                "bb0535": {
                    "endOffset": 60044,
                    "startOffset": 60032
                }
            },
            "secId": "s0120",
            "sentence": "Two other covalent heparin coatings with established surface heparin activity were used on coronary stents and had a similar clinical experience [38,104\u2013107].",
            "startOffset": 59887,
            "title": "Coronary stents"
        },
        {
            "endOffset": 67179,
            "parents": [],
            "secId": "s0135",
            "sentence": "ASTUTE\u2122 is a trademark of Biointeractions Ltd.",
            "startOffset": 67133,
            "title": "Conclusions"
        },
        {
            "endOffset": 25646,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 25580,
                    "startOffset": 25575
                },
                "bb0010": {
                    "endOffset": 25580,
                    "startOffset": 25575
                },
                "bb0015": {
                    "endOffset": 25580,
                    "startOffset": 25575
                },
                "bb0025": {
                    "endOffset": 25645,
                    "startOffset": 25640
                },
                "bb0030": {
                    "endOffset": 25645,
                    "startOffset": 25640
                },
                "bb0035": {
                    "endOffset": 25645,
                    "startOffset": 25640
                },
                "bb0040": {
                    "endOffset": 25645,
                    "startOffset": 25640
                }
            },
            "secId": "s0005",
            "sentence": "Numerous approaches to hemocompatible surface modifications have been described since [1\u20133], including a number of heparin-based surface modifications [5\u20138].",
            "startOffset": 25489,
            "title": "Introduction"
        },
        {
            "endOffset": 31529,
            "parents": [],
            "secId": "s0015",
            "sentence": "Heparin immobilization technologies can be divided into two broad categories: eluting technologies that release heparin from the device and non-eluting technologies intended for permanent covalent immobilization of heparin to the device surface.",
            "startOffset": 31284,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 45286,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0075",
            "sentence": "This raises the possibility that an inactive heparin surface that retains heparin's net negative charge may have the unintended consequence of promoting coagulation rather than preventing it.",
            "startOffset": 45095,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 46195,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0025": {
                    "endOffset": 46046,
                    "startOffset": 46043
                },
                "bb0290": {
                    "endOffset": 46194,
                    "startOffset": 46190
                }
            },
            "secId": "s0080",
            "sentence": "The heparin-based mechanism for this effect is believed to be an indirect result of inhibition of the contact activation pathway, which can trigger activation of the complement cascade [5] as well direct inhibition of complement proteins by other serine protease inhibitors enriched on the EPA-heparin surface, such as C1-inhibitor [58].",
            "startOffset": 45858,
            "title": "Reduced complement activation and inflammation"
        },
        {
            "endOffset": 65559,
            "parents": [],
            "secId": "s0130",
            "sentence": "Numerous cases of delayed onset HIT have been reported in patients for which heparin has been discontinued and no heparin coated devices have been implanted.",
            "startOffset": 65402,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 65805,
            "parents": [],
            "refoffsets": {
                "bb0585": {
                    "endOffset": 65804,
                    "startOffset": 65799
                }
            },
            "secId": "s0130",
            "sentence": "Analysis of the suspected delayed onset HIT cases associated with the presence of devices coated with the CBAS Heparin Surface called into question whether the devices contributed to the condition or their presence was simply coincidental [117].",
            "startOffset": 65560,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 37413,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0165": {
                    "endOffset": 37412,
                    "startOffset": 37408
                }
            },
            "secId": "s0035",
            "sentence": "The coating process involves first preconditioning the surface with a layer of cationic polyamine and then attaching the pre-formed heparin complexes to the polyamine through ionic interactions [33].",
            "startOffset": 37214,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 52943,
            "parents": [],
            "secId": "s0095",
            "sentence": "The net result of these acute protein interactions may contribute to the long-term remodeling that takes place chronically on blood contacting surfaces coated with the CBAS Heparin Surface.",
            "startOffset": 52754,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 51066,
            "parents": [],
            "secId": "s0090",
            "sentence": "The level of AT binding required to mitigate against these effects will thus likely vary between technologies.",
            "startOffset": 50956,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 29993,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 29992,
                    "startOffset": 29988
                }
            },
            "secId": "s0010",
            "sentence": "The anticoagulant function of heparin is dependent on a specific sequence of five sugars (the so-called pentasaccharide sequence), which are required for efficient binding of antithrombin (AT) [15].",
            "startOffset": 29795,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 25079,
            "parents": [],
            "secId": "s0005",
            "sentence": "Bioactive strategies employ direct pharmacologic inhibition of the coagulation response by local drug delivery or permanent immobilization of an active agent.",
            "startOffset": 24921,
            "title": "Introduction"
        },
        {
            "endOffset": 64825,
            "parents": [],
            "refoffsets": {
                "bb0585": {
                    "endOffset": 64824,
                    "startOffset": 64819
                }
            },
            "secId": "s0130",
            "sentence": "In all but one of the cases, the timing of events and assay results were suggestive of delayed-onset HIT [117].",
            "startOffset": 64714,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 55864,
            "parents": [],
            "secId": "s0105",
            "sentence": "The CBAS Heparin Surface has been successfully used on a number of blood contacting medical devices and substrates for both acute and chronic settings.",
            "startOffset": 55713,
            "title": "Performance of CBAS Heparin Surfaces in vivo"
        },
        {
            "endOffset": 33144,
            "parents": [],
            "refoffsets": {
                "bb0120": {
                    "endOffset": 33143,
                    "startOffset": 33136
                },
                "bb0125": {
                    "endOffset": 33143,
                    "startOffset": 33136
                }
            },
            "secId": "s0015",
            "sentence": "For example, the carbodiimide crosslinker EDC has been used to activate carboxyl groups along the heparin chain and then conjugate to amines incorporated into the target surface [24,25].",
            "startOffset": 32958,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 45636,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0255": {
                    "endOffset": 45635,
                    "startOffset": 45631
                }
            },
            "secId": "s0080",
            "sentence": "The earliest clinical applications of heparin surfaces was on materials used in extracorporeal circulation, where the high surface area exposure to the polymeric materials of the circuits was known to trigger systemic inflammation due to complement activation and cellular inflammatory reactions [51].",
            "startOffset": 45335,
            "title": "Reduced complement activation and inflammation"
        },
        {
            "endOffset": 60774,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0125",
            "sentence": "Primary modes of failure include occlusion of the graft lumen by thrombus or intimal hyperplasia, both of which contribute to reduced patency.",
            "startOffset": 60632,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 28214,
            "parents": [],
            "secId": "s0010",
            "sentence": "This cascade consists of two pathways, the intrinsic and extrinsic, each of which is triggered by different mechanisms.",
            "startOffset": 28095,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 38801,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0180": {
                    "endOffset": 38800,
                    "startOffset": 38796
                }
            },
            "secId": "s0045",
            "sentence": "The process involves application of a photoreagent to the substrate followed by UV illumination under wet or dry conditions [36].",
            "startOffset": 38672,
            "title": "Surmodics Photolink\u00ae Heparin Coating"
        },
        {
            "endOffset": 45857,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0260": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0265": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0270": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0275": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0280": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0285": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0290": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0295": {
                    "endOffset": 45804,
                    "startOffset": 45797
                },
                "bb0300": {
                    "endOffset": 45856,
                    "startOffset": 45849
                },
                "bb0305": {
                    "endOffset": 45856,
                    "startOffset": 45849
                }
            },
            "secId": "s0080",
            "sentence": "Using in vitro models, EPA-heparin has been shown to reduce complement activation (C3 activation products, C5 activation products, terminal complement complex) [52\u201359] as well as cellular markers of inflammation [60,61].",
            "startOffset": 45637,
            "title": "Reduced complement activation and inflammation"
        },
        {
            "endOffset": 63199,
            "parents": [],
            "secId": "s0130",
            "sentence": "For devices incorporating heparin, there is a paucity of published studies on whether covalently immobilized heparin may cause or contribute to the condition.",
            "startOffset": 63041,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 67056,
            "parents": [],
            "secId": "s0135",
            "sentence": "CARMEDA\u00ae and CBAS\u00ae are trademarks of Carmeda AB, a wholly owned subsidiary of W.L. Gore & Associates, Inc.",
            "startOffset": 66950,
            "title": "Conclusions"
        },
        {
            "endOffset": 54342,
            "parents": [],
            "secId": "s0100",
            "sentence": "Hence it is not only important to demonstrate AT uptake initially, but to ensure that sufficient levels are maintained throughout processing and shelf life of the product.",
            "startOffset": 54171,
            "title": "Product considerations"
        },
        {
            "endOffset": 50955,
            "parents": [],
            "secId": "s0090",
            "sentence": "Other chemical groups, surface charge, surface coverage, and specific flow dynamics associated with a specific coating technology may also influence the reactivity of the surface with blood components.",
            "startOffset": 50754,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 29683,
            "parents": [],
            "secId": "s0010",
            "sentence": "Unlike heparan sulfate, heparin is largely intracellular, within the granules of mast cells.",
            "startOffset": 29591,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 41325,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The base matrix can be deposited on diverse types of materials (polymers, metals, glass).",
            "startOffset": 41236,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 30346,
            "parents": [],
            "secId": "s0010",
            "sentence": "Binding of AT to the heparin pentasaccharide sequence causes a conformational change in the AT molecule and greatly accelerates the rate of AT-mediated inhibition of the various serine protease clotting factors by a factor of 100\u20131000.",
            "startOffset": 30111,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 58292,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0115",
            "sentence": "However, serious thromboembolic events still occur.",
            "startOffset": 58241,
            "title": "Ventricular assist devices"
        },
        {
            "endOffset": 39701,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0055",
            "sentence": "The coating consists of a poly(vinylsiloxane) that is first covalently attached to the stent surface.",
            "startOffset": 39600,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 28644,
            "parents": [],
            "secId": "s0010",
            "sentence": "Contact activation of FXII, together with kallikrein and high molecular weight kininogen (HMWK), initiates the intrinsic pathway leading to activation of FX, and consequently conversion of prothrombin into thrombin.",
            "startOffset": 28429,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 48398,
            "parents": [],
            "secId": "s0090",
            "sentence": "Further evaluation of the surfaces after blood contact revealed that antithrombin uptake from blood was only detectable on the end-point attached heparin surface, further indicating that loss of heparin functionality is possible with some linking chemistries (Fig. 4).",
            "startOffset": 48130,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 28428,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 28427,
                    "startOffset": 28424
                }
            },
            "secId": "s0010",
            "sentence": "The intrinsic pathway is considered the more critical pathway in biomaterial-associated thrombosis [1].",
            "startOffset": 28325,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 51486,
            "parents": [],
            "refoffsets": {
                "bb0350": {
                    "endOffset": 51410,
                    "startOffset": 51406
                },
                "bb0355": {
                    "endOffset": 51485,
                    "startOffset": 51481
                }
            },
            "secId": "s0095",
            "sentence": "Heparin-protein interactions occur through non-specific ionic interactions (because of heparin's strong anionic character) [70] and through sequence-specific high affinity interactions (as with AT) [71].",
            "startOffset": 51283,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 62037,
            "parents": [],
            "secId": "s0130",
            "sentence": "There are risks associated with the use of heparin, including the rare but potentially life threatening complication of Heparin Induced Thrombocytopenia (HIT).",
            "startOffset": 61878,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 30110,
            "parents": [],
            "refoffsets": {
                "bb0080": {
                    "endOffset": 30109,
                    "startOffset": 30102
                },
                "bb0085": {
                    "endOffset": 30109,
                    "startOffset": 30102
                },
                "bb0090": {
                    "endOffset": 30109,
                    "startOffset": 30102
                }
            },
            "secId": "s0010",
            "sentence": "This sequence is only found in approximately one-third of the molecules in a commercial heparin preparation [16\u201318].",
            "startOffset": 29994,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 31916,
            "parents": [],
            "secId": "s0015",
            "sentence": "For example, complexes of heparin with branched surfactants bearing quaternary ammonium groups can be deposited on a material surface.",
            "startOffset": 31782,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 37213,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0035",
            "sentence": "The ratio of heparin to polyamine carrier is approximately 70 molecules of heparin coupled to a polyamine carrier chain.",
            "startOffset": 37093,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 43514,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0225": {
                    "endOffset": 43421,
                    "startOffset": 43417
                },
                "bb0230": {
                    "endOffset": 43513,
                    "startOffset": 43509
                }
            },
            "secId": "s0070",
            "sentence": "Studies of EPA-heparin under controlled conditions in vitro have demonstrated that the inhibitory capacity of EPA-heparin toward activated clotting factors is limited by convective transport of reactants [45] and flow rate has a strong influence on the uptake of antithrombin (AT) on the surface [46].",
            "startOffset": 43213,
            "title": "Reaction kinetics"
        },
        {
            "endOffset": 32054,
            "parents": [],
            "secId": "s0015",
            "sentence": "Blood contact causes release of the ionic complex from the surface, but the presence of the surfactant slows the rate of heparin release.",
            "startOffset": 31917,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 38118,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0040",
            "sentence": "The Flowline BIPORE\u00ae Heparin Surface (Jotec GmbH) is described as heparin that is bonded through covalent and ionic interactions to the substrate.",
            "startOffset": 37972,
            "title": "Flowline BIPORE\u00ae Heparin Surface"
        },
        {
            "endOffset": 38500,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0040",
            "sentence": "This heparin surface is marketed by Jotec as the Flowline BIPORE\u00ae Heparin ePTFE vascular graft with heparin coating.",
            "startOffset": 38384,
            "title": "Flowline BIPORE\u00ae Heparin Surface"
        },
        {
            "endOffset": 42486,
            "parents": [],
            "secId": "s0065",
            "sentence": "The following sections review in vitro studies of the end-point attached (EPA) heparin of the CBAS Heparin Surface which elucidated the basic mechanisms by which EPA-heparin acts in blood, including additional features not associated with freely soluble heparin that is administered systemically.",
            "startOffset": 42190,
            "title": "Mechanism and properties of covalent heparin surfaces"
        },
        {
            "endOffset": 50352,
            "parents": [],
            "refoffsets": {
                "bb0225": {
                    "endOffset": 50234,
                    "startOffset": 50230
                }
            },
            "secId": "s0090",
            "sentence": "This may also be explained by kinetic modeling of covalently bonded heparin surfaces, which demonstrated that above a specific surface concentration of AT, reactant flux to the surface was rate limiting [45], and hence increasingly higher levels of AT uptake would not necessarily contribute to any further biological effect.",
            "startOffset": 50027,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 53936,
            "parents": [],
            "secId": "s0100",
            "sentence": "Specific considerations for a heparin coating include demonstration that the coating is sufficiently durable to survive downstream product processing and shelf life, including mechanical manipulation, sterilization, and packaging.",
            "startOffset": 53706,
            "title": "Product considerations"
        },
        {
            "endOffset": 55090,
            "parents": [],
            "secId": "s0100",
            "sentence": "This catalytic activity of heparin is the key feature of its attractiveness for permanent covalent immobilization.",
            "startOffset": 54976,
            "title": "Product considerations"
        },
        {
            "endOffset": 36335,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0150": {
                    "endOffset": 36334,
                    "startOffset": 36327
                },
                "bb0155": {
                    "endOffset": 36334,
                    "startOffset": 36327
                }
            },
            "secId": "s0030",
            "sentence": "The technology consists of a recombinant human albumin coating to which heparin is covalently attached [30,31].",
            "startOffset": 36224,
            "title": "Maquet BIOLINE\u00ae Coating"
        },
        {
            "endOffset": 37092,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0160": {
                    "endOffset": 37091,
                    "startOffset": 37087
                }
            },
            "secId": "s0035",
            "sentence": "The CHS\u2122 surface is composed of macromolecular complexes of unfractionated heparin covalently attached via a heterobifunctional crosslinker to a polyamine carrier chain [32].",
            "startOffset": 36918,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 61722,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0560": {
                    "endOffset": 61721,
                    "startOffset": 61716
                }
            },
            "secId": "s0125",
            "sentence": "Retrospective multicenter analyses of the GORE\u00ae PROPATEN\u00ae Vascular Graft have also demonstrated patency rates comparable to autologous vein [112].",
            "startOffset": 61576,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 53213,
            "parents": [],
            "refoffsets": {
                "bb0215": {
                    "endOffset": 52994,
                    "startOffset": 52990
                },
                "bb0365": {
                    "endOffset": 53203,
                    "startOffset": 53199
                }
            },
            "secId": "s0095",
            "sentence": "In the same model described by Begovac et al. [43], which demonstrated improved patency at 6 months and sustained AT uptake on vascular grafts for at least 3 months in vivo, there was significantly reduced protein deposition compared to uncoated controls [73] (Fig. 5).",
            "startOffset": 52944,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 43674,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0070",
            "sentence": "This has implications on the relationship between surface AT uptake capacity and performance measures of the surface in blood (discussed further in Section 6).",
            "startOffset": 43515,
            "title": "Reaction kinetics"
        },
        {
            "endOffset": 64420,
            "parents": [],
            "refoffsets": {
                "bb0590": {
                    "endOffset": 64419,
                    "startOffset": 64414
                }
            },
            "secId": "s0130",
            "sentence": "Furthermore, in both the CBAS Heparin Surface group and the uncoated group, approximately 66% of the patients who were initially positive for anti-PF4/heparin antibodies became seronegative after systemic injectable heparin was discontinued [118].",
            "startOffset": 64173,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 63600,
            "parents": [],
            "refoffsets": {
                "bb0585": {
                    "endOffset": 63599,
                    "startOffset": 63594
                }
            },
            "secId": "s0130",
            "sentence": "Definitive conclusions are difficult to draw because interpretation is confounded by the near ubiquitous use of relatively large doses of injectable heparin prior to, during, and after implantation of heparin coated devices [117].",
            "startOffset": 63370,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 59374,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0220": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0485": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0490": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0495": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0500": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0505": {
                    "endOffset": 59373,
                    "startOffset": 59362
                },
                "bb0510": {
                    "endOffset": 59373,
                    "startOffset": 59362
                }
            },
            "secId": "s0120",
            "sentence": "Studies on a number of different stents indicated coating with the CBAS Heparin surface resulted in improvement in thrombosis, reduced platelet deposition, and reduced intimal hyperplasia in animal models [44,97\u2013102].",
            "startOffset": 59157,
            "title": "Coronary stents"
        },
        {
            "endOffset": 40665,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0195": {
                    "endOffset": 40664,
                    "startOffset": 40660
                }
            },
            "secId": "s0060",
            "sentence": "The Carmeda heparin binding approach employs a single covalent bond between the reducing end of the heparin molecule and the material substrate [39].",
            "startOffset": 40516,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 62886,
            "parents": [],
            "refoffsets": {
                "bb0575": {
                    "endOffset": 62885,
                    "startOffset": 62880
                }
            },
            "secId": "s0130",
            "sentence": "If circulating antibodies have disappeared, history of HIT does not predict formation of antibodies upon re-exposure to heparin [115].",
            "startOffset": 62752,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 25814,
            "parents": [],
            "secId": "s0005",
            "sentence": "The focus of this review is on a specific subset of commercialized non-eluting heparin coating technologies which were developed for use in the medical device industry.",
            "startOffset": 25646,
            "title": "Introduction"
        },
        {
            "endOffset": 35136,
            "parents": [],
            "secId": "s0020",
            "sentence": "The amount of available published information, particularly of a technical nature, differs widely between the commercial technologies and as a result, a comprehensive comparison among them is not entirely possible.",
            "startOffset": 34922,
            "title": "Commercial heparin coating technologies"
        },
        {
            "endOffset": 54735,
            "parents": [],
            "secId": "s0100",
            "sentence": "For this reason, biochemical activity must also be verified by performance testing in blood and other appropriate preclinical models.",
            "startOffset": 54602,
            "title": "Product considerations"
        },
        {
            "endOffset": 62707,
            "parents": [],
            "secId": "s0130",
            "sentence": "Anti-PF4/heparin antibodies persist only briefly, disappearing from circulation between 50 and 85 days.",
            "startOffset": 62604,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 63369,
            "parents": [],
            "secId": "s0130",
            "sentence": "Available data have not demonstrated a causal relationship between covalently immobilized heparin and either the initial immunizing event or exacerbation of ongoing HIT.",
            "startOffset": 63200,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 64624,
            "parents": [],
            "refoffsets": {
                "bb0600": {
                    "endOffset": 64623,
                    "startOffset": 64614
                },
                "bb0605": {
                    "endOffset": 64623,
                    "startOffset": 64614
                },
                "bb0610": {
                    "endOffset": 64623,
                    "startOffset": 64614
                }
            },
            "secId": "s0130",
            "sentence": "Several case reports on the GORE\u00ae PROPATEN\u00ae Vascular Graft, which contains the CBAS Heparin Surface, suggested that the presence of the covalently bonded heparin on the graft contributed to HIT [120\u2013122].",
            "startOffset": 64420,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 39076,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0045",
            "sentence": "Surmodics coatings have been used on commercial medical devices throughout the world, although specific information on which devices use the Surmodics technology are not disclosed.",
            "startOffset": 38896,
            "title": "Surmodics Photolink\u00ae Heparin Coating"
        },
        {
            "endOffset": 55324,
            "parents": [],
            "refoffsets": {
                "bb0215": {
                    "endOffset": 55252,
                    "startOffset": 55248
                },
                "bb0370": {
                    "endOffset": 55323,
                    "startOffset": 55316
                },
                "bb0375": {
                    "endOffset": 55323,
                    "startOffset": 55316
                }
            },
            "secId": "s0100",
            "sentence": "In a series of chronic implant studies, it was shown that AT-uptake was retained on the CBAS Heparin Surface of ePTFE vascular grafts after 3 months in vivo [43] and after at least 1 year in ventricular assist devices (VADs) [74,75].",
            "startOffset": 55091,
            "title": "Product considerations"
        },
        {
            "endOffset": 32273,
            "parents": [],
            "secId": "s0015",
            "sentence": "The alternative approach intended to confer long-term surface thromboresistance is to permanently immobilize heparin to the device surface.",
            "startOffset": 32134,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 26193,
            "parents": [],
            "secId": "s0005",
            "sentence": "Hence, this review will focus on the immobilization of the anticoagulant drug heparin with emphasis on the CBAS Heparin Surface.",
            "startOffset": 26065,
            "title": "Introduction"
        },
        {
            "endOffset": 60362,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0125",
            "sentence": "Synthetic grafts composed of ePTFE provided favorable outcomes in peripheral bypass, but nevertheless produced lower patency rates than autologous vein.",
            "startOffset": 60210,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 27243,
            "parents": [],
            "refoffsets": {
                "bb0050": {
                    "endOffset": 27242,
                    "startOffset": 27238
                }
            },
            "secId": "s0010",
            "sentence": "Activated platelets undergo dramatic shape changes which promote aggregation with other platelets, and release platelet and pro-coagulant agonists (such as thromboxane A2, ADP, and FVa) [10].",
            "startOffset": 27052,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 65119,
            "parents": [],
            "secId": "s0130",
            "sentence": "It is frequently observed that patients with this condition experience declining platelet count and ongoing hypercoagulability even after heparin is discontinued.",
            "startOffset": 64957,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 27051,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 27050,
                    "startOffset": 27045
                },
                "bb0010": {
                    "endOffset": 27050,
                    "startOffset": 27045
                },
                "bb0045": {
                    "endOffset": 26882,
                    "startOffset": 26879
                }
            },
            "secId": "s0010",
            "sentence": "It is well known that blood contact with artificial surfaces can elicit platelet activation by a variety of mechanisms [1], including device related alteration in blood flow that trigger shear-related platelet activation [9], and due to direct platelet adherence to the deposited protein layer on synthetic surfaces of the device, an event largely attributed to adsorption of fibrinogen [1,2].",
            "startOffset": 26658,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 61575,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0555": {
                    "endOffset": 61574,
                    "startOffset": 61569
                }
            },
            "secId": "s0125",
            "sentence": "A prospective randomized trial across 11 centers in Scandinavia demonstrated significantly improved patency of the GORE\u00ae PROPATEN\u00ae Vascular Graft compared with uncoated control in patients with critical limb ischemia [111].",
            "startOffset": 61352,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 65401,
            "parents": [],
            "refoffsets": {
                "bb0585": {
                    "endOffset": 65400,
                    "startOffset": 65395
                }
            },
            "secId": "s0130",
            "sentence": "In one reported case of HIT associated with the GORE\u00ae PROPATEN\u00ae Vascular Graft, a follow-up investigation of the patient's serum confirmed a serological profile consistent with delayed onset HIT, again calling into question the role of the graft in contributing to the event [117].",
            "startOffset": 65120,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 67801,
            "parents": [],
            "secId": "s0135",
            "sentence": "DURAFLO\u00ae II is a registered trademark of Edwards Lifesciences, LLC",
            "startOffset": 67735,
            "title": "Conclusions"
        },
        {
            "endOffset": 57366,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0435": {
                    "endOffset": 57365,
                    "startOffset": 57361
                }
            },
            "secId": "s0110",
            "sentence": "Despite a wealth of strong in vitro data demonstrating reductions in adverse blood reaction to various heparin coated circuits, widespread and consistent clinical benefit in the hands of different research groups has not been as clear, and there is a lack of studies that directly compare the performance attributes of different heparin coated circuits [87].",
            "startOffset": 57008,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 29050,
            "parents": [],
            "secId": "s0010",
            "sentence": "A key inhibitor of the clotting factors is the plasma serine protease inhibitor antithrombin (AT).",
            "startOffset": 28952,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 59886,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0120",
            "sentence": "This was due in part to difficulty in effectively powering studies because of the overall low rates of acute thrombosis.",
            "startOffset": 59766,
            "title": "Coronary stents"
        },
        {
            "endOffset": 36842,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0035",
            "sentence": "The CORLINE\u00ae Heparin Surface (CHS\u2122), developed by the Swedish company Corline Systems, AB, has been in clinic use since 1997.",
            "startOffset": 36717,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 57712,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0445": {
                    "endOffset": 57711,
                    "startOffset": 57707
                }
            },
            "secId": "s0110",
            "sentence": "In a more contemporary review of the subject, there continue to be improved outcomes associated with heparin coated surfaces [89].",
            "startOffset": 57582,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 41027,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The depolymerized heparin is subsequently covalently bonded by reductive amination to a substrate that contains amine functional groups.",
            "startOffset": 40891,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 52198,
            "parents": [],
            "refoffsets": {
                "bb0285": {
                    "endOffset": 52197,
                    "startOffset": 52193
                },
                "bb0290": {
                    "endOffset": 51955,
                    "startOffset": 51951
                }
            },
            "secId": "s0095",
            "sentence": "Weber et al. [58] proposed that binding (or notable absence) of certain plasma proteins may also contribute to the mechanism of action, most notably the absence or reduced binding of platelet adhesive proteins such as fibrinogen and complement protein C3 [57].",
            "startOffset": 51938,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 52390,
            "parents": [],
            "refoffsets": {
                "bb0285": {
                    "endOffset": 52389,
                    "startOffset": 52385
                }
            },
            "secId": "s0095",
            "sentence": "Previous studies have demonstrated differences in the uptake of these proteins between various heparin technologies, with lowest binding of fibrinogen and C3 on the CBAS Heparin Surface [57].",
            "startOffset": 52199,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 36683,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0025": {
                    "endOffset": 36634,
                    "startOffset": 36631
                }
            },
            "secId": "s0030",
            "sentence": "In a previous review it was noted that heparin used is of high molecular weight and that the bonding approach preserves the active sequence of the heparin [5], however no supporting information was provided.",
            "startOffset": 36476,
            "title": "Maquet BIOLINE\u00ae Coating"
        },
        {
            "endOffset": 57008,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0415": {
                    "endOffset": 56869,
                    "startOffset": 56862
                },
                "bb0420": {
                    "endOffset": 56869,
                    "startOffset": 56862
                },
                "bb0425": {
                    "endOffset": 56869,
                    "startOffset": 56862
                },
                "bb0430": {
                    "endOffset": 57007,
                    "startOffset": 57003
                }
            },
            "secId": "s0110",
            "sentence": "In addition, it was demonstrated that systemic heparin dosing could be reduced or eliminated without adverse coagulation or inflammatory responses [83\u201385] and resulted in a lower rate of blood loss requiring transfusion, shorter hospitalization periods, and improvement in treatment cost [86].",
            "startOffset": 56715,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 38271,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0040",
            "sentence": "This presumably involves an intermediate adhesive layer between the device surface and the heparin, but the nature of this layer has not been published.",
            "startOffset": 38119,
            "title": "Flowline BIPORE\u00ae Heparin Surface"
        },
        {
            "endOffset": 27719,
            "parents": [],
            "secId": "s0010",
            "sentence": "Aggregation of platelets, together with explosive activation of protein clotting factors, may result in significant thrombus accumulation on the device surface, embolization of thrombus particles into the bloodstream, and may cause detectable reductions in circulating platelet count (consumption of platelets).",
            "startOffset": 27408,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 39291,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0050",
            "sentence": "The PM\u00ae Flow Plus Heparin Surface used by the French company Perouse Medical (acquired by the Vygon Group in 2015) is a covalent heparin surface used on ePTFE vascular grafts.",
            "startOffset": 39116,
            "title": "Perouse POLYMAILLE\u00ae Flow Plus Heparin"
        },
        {
            "endOffset": 54170,
            "parents": [],
            "secId": "s0100",
            "sentence": "Here multiple mechanisms may be involved in the deterioration of heparin activity: chemical degradation, chemical modification or reduced availability of the active site, and mechanical damage to the coating (i.e. loss of integrity).",
            "startOffset": 53937,
            "title": "Product considerations"
        },
        {
            "endOffset": 58880,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0460": {
                    "endOffset": 58879,
                    "startOffset": 58872
                },
                "bb0465": {
                    "endOffset": 58879,
                    "startOffset": 58872
                },
                "bb0470": {
                    "endOffset": 58879,
                    "startOffset": 58872
                },
                "bb0475": {
                    "endOffset": 58879,
                    "startOffset": 58872
                }
            },
            "secId": "s0120",
            "sentence": "What were initially high acute thrombosis (SAT) rates with the first generations of metallic stents was reduced due to improvements in stent placement techniques, product design enhancements, and effective dual antiplatelet therapy [92\u201395].",
            "startOffset": 58640,
            "title": "Coronary stents"
        },
        {
            "endOffset": 67231,
            "parents": [],
            "secId": "s0135",
            "sentence": "TRILLIUM\u00ae is a registered trademark of Medtronic plc",
            "startOffset": 67179,
            "title": "Conclusions"
        },
        {
            "endOffset": 67735,
            "parents": [],
            "secId": "s0135",
            "sentence": "PM\u00ae is a registered trademark of Perouse Medical",
            "startOffset": 67687,
            "title": "Conclusions"
        },
        {
            "endOffset": 30483,
            "parents": [],
            "secId": "s0010",
            "sentence": "Importantly, heparin is not consumed in the reaction and is capable of continuously catalyzing inhibition of activated clotting factors.",
            "startOffset": 30347,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 35690,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0140": {
                    "endOffset": 35689,
                    "startOffset": 35685
                }
            },
            "secId": "s0025",
            "sentence": "Sulfonate bearing groups, PEG chains, and heparin molecules are covalently attached to the priming layer [28].",
            "startOffset": 35580,
            "title": "BioInteractions ASTUTE\u00ae Advanced Heparin Coating/Medtronic Trillium\u00ae Biosurface"
        },
        {
            "endOffset": 28094,
            "parents": [],
            "secId": "s0010",
            "sentence": "After vascular injury, or through the introduction of foreign materials into the circulatory system, clotting factors are triggered and undergo activation in a sequential cascade-like fashion that culminates in the formation of a fibrin clot.",
            "startOffset": 27852,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 61351,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0200": {
                    "endOffset": 61350,
                    "startOffset": 61346
                }
            },
            "secId": "s0125",
            "sentence": "Extensive clinical evaluation of ePTFE vascular grafts coated with the CBAS Heparin Surface have shown improved patency relative to uncoated grafts [40].",
            "startOffset": 61198,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 29794,
            "parents": [],
            "secId": "s0010",
            "sentence": "Heparin consists primarily of two highly sulfated sugar monomers, which occur as repeating disaccharide units.",
            "startOffset": 29684,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 39944,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0185": {
                    "endOffset": 39943,
                    "startOffset": 39939
                }
            },
            "secId": "s0055",
            "sentence": "Finally, heparin is covalently coupled to the polyethyleneimine [37].",
            "startOffset": 39875,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 44951,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0075",
            "sentence": "An important lesson from the studies of contact activation is that functionally inactive immobilized heparin may actually accelerate activation of the intrinsic pathway by virtue of the strong net negative charge imparted on the surface.",
            "startOffset": 44714,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 24712,
            "parents": [],
            "refoffsets": {
                "bb0015": {
                    "endOffset": 24711,
                    "startOffset": 24708
                }
            },
            "secId": "s0005",
            "sentence": "Surface modification technologies can be assigned into two broad categories: passivation of material surfaces and bioactive surface treatments and coatings [3].",
            "startOffset": 24552,
            "title": "Introduction"
        },
        {
            "endOffset": 56200,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0255": {
                    "endOffset": 56199,
                    "startOffset": 56195
                }
            },
            "secId": "s0110",
            "sentence": "Blood exposure to a high surface area of polymeric materials of extracorporeal circuits is known to trigger systemic inflammation due in part to complement activation [51].",
            "startOffset": 56028,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 61197,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0545": {
                    "endOffset": 61196,
                    "startOffset": 61187
                },
                "bb0550": {
                    "endOffset": 61196,
                    "startOffset": 61187
                }
            },
            "secId": "s0125",
            "sentence": "Animal models also demonstrated that the CBAS Heparin Surface reduced platelet attachment and peri-anastomotic intimal hyperplasia on ePTFE vascular grafts [109,110].",
            "startOffset": 61031,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 67383,
            "parents": [],
            "secId": "s0135",
            "sentence": "HYDRAGLIDE\u00ae is a registered trademark of Atrium Medical (Maquet Getinge Group)",
            "startOffset": 67305,
            "title": "Conclusions"
        },
        {
            "endOffset": 40750,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "Unfractionated heparin is first partially depolymerized by nitrous acid deamination.",
            "startOffset": 40666,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 66027,
            "parents": [],
            "secId": "s0135",
            "sentence": "Decades of investigation and clinical experience with covalently bonded heparin coatings have demonstrated the basic mechanisms and clinical benefits of this technology in a number medical device applications.",
            "startOffset": 65818,
            "title": "Conclusions"
        },
        {
            "endOffset": 24551,
            "parents": [],
            "secId": "s0005",
            "sentence": "Modification of medical device surfaces to improve blood compatibility has been sought to reduce device-related thrombus formation and inflammatory reactions.",
            "startOffset": 24393,
            "title": "Introduction"
        },
        {
            "endOffset": 42658,
            "parents": [],
            "secId": "s0065",
            "sentence": "Among the various commercialized heparin bonding technologies, the bulk of published research on basic mechanisms of action comes from studies of the CBAS Heparin Surface.",
            "startOffset": 42487,
            "title": "Mechanism and properties of covalent heparin surfaces"
        },
        {
            "endOffset": 44283,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0250": {
                    "endOffset": 44282,
                    "startOffset": 44278
                }
            },
            "secId": "s0075",
            "sentence": "Contact with negatively charged surfaces by key initiators of the intrinsic pathway (high molecular weight kininogen, prekallikrein, and FXII) is required for activation [50].",
            "startOffset": 44108,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 51282,
            "parents": [],
            "refoffsets": {
                "bb0345": {
                    "endOffset": 51281,
                    "startOffset": 51277
                }
            },
            "secId": "s0095",
            "sentence": "Heparin is known to bind to many proteins, including protease inhibitors other than antithrombin (AT), enzymes, growth factors, chemokines, and a variety of pathogen proteins [69].",
            "startOffset": 51102,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 55989,
            "parents": [],
            "secId": "s0105",
            "sentence": "This includes hemodialysis catheters, peripheral and coronary vascular stents, stent grafts, and ventricular assist devices.",
            "startOffset": 55865,
            "title": "Performance of CBAS Heparin Surfaces in vivo"
        },
        {
            "endOffset": 42736,
            "parents": [],
            "secId": "s0065",
            "sentence": "The remainder of the review will focus almost exclusively on this technology.",
            "startOffset": 42659,
            "title": "Mechanism and properties of covalent heparin surfaces"
        },
        {
            "endOffset": 62292,
            "parents": [],
            "secId": "s0130",
            "sentence": "It is caused by antibodies that form in response to complexes of heparin and platelet factor 4 (PF4).",
            "startOffset": 62191,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 38895,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0045",
            "sentence": "This approach has been used by Surmodics to produce a covalently immobilized heparin surface.",
            "startOffset": 38802,
            "title": "Surmodics Photolink\u00ae Heparin Coating"
        },
        {
            "endOffset": 53705,
            "parents": [],
            "secId": "s0100",
            "sentence": "Many of these requirements are part of international and regional standards required by regulatory bodies.",
            "startOffset": 53599,
            "title": "Product considerations"
        },
        {
            "endOffset": 25293,
            "parents": [],
            "refoffsets": {
                "bb0020": {
                    "endOffset": 25292,
                    "startOffset": 25289
                }
            },
            "secId": "s0005",
            "sentence": "A precipitating event in the modern field of blood compatible surface modifications was the serendipitous discovery of the thromboresistant properties of a heparin coated surface by Gott and colleagues in 1963 [4].",
            "startOffset": 25079,
            "title": "Introduction"
        },
        {
            "endOffset": 33627,
            "parents": [],
            "secId": "s0015",
            "sentence": "Chemical modification or obstruction of the critical pentasaccharide sequence will reduce or eliminate the ability of heparin to bind antithrombin (AT).",
            "startOffset": 33475,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 64713,
            "parents": [],
            "secId": "s0130",
            "sentence": "These cases involved the use of systemic heparin perioperatively and/or postoperatively.",
            "startOffset": 64625,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 24137,
            "parents": [],
            "secId": "s0005",
            "sentence": "This may manifest clinically as thrombotic occlusion and embolization across a spectrum of cardiovascular medical devices, including vascular stents, grafts, and catheters, as well as cardiopulmonary bypass and oxygenation equipment, prosthetic valves, and ventricular assist devices.",
            "startOffset": 23853,
            "title": "Introduction"
        },
        {
            "endOffset": 29590,
            "parents": [],
            "refoffsets": {
                "bb0070": {
                    "endOffset": 29589,
                    "startOffset": 29585
                }
            },
            "secId": "s0010",
            "sentence": "Heparin is a naturally occurring linear polysaccharide that shares chemical and structural similarity to heparan sulfate, a cell surface proteoglycan that provides the natural anticoagulant surface activity of the vascular endothelium [14].",
            "startOffset": 29350,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 37561,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0170": {
                    "endOffset": 37560,
                    "startOffset": 37553
                },
                "bb0175": {
                    "endOffset": 37560,
                    "startOffset": 37553
                }
            },
            "secId": "s0035",
            "sentence": "The result is a non-leaching surface, and published reports have demonstrated detectable heparin density and AT uptake on the CHS\u2122 surface [34,35].",
            "startOffset": 37414,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 46349,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 46348,
                    "startOffset": 46345
                }
            },
            "secId": "s0080",
            "sentence": "This may also have downstream effects on cellular elements of inflammation, as inhibition of complement reduces adhesion of granulocytes to surfaces [6].",
            "startOffset": 46196,
            "title": "Reduced complement activation and inflammation"
        },
        {
            "endOffset": 54975,
            "parents": [],
            "secId": "s0100",
            "sentence": "Because it is not consumed in the AT-mediated inhibition of clotting factors, immobilized functionally active heparin should in theory render a surface thromboresistant over extended periods of time if the heparin is not otherwise degraded.",
            "startOffset": 54735,
            "title": "Product considerations"
        },
        {
            "endOffset": 51937,
            "parents": [],
            "secId": "s0095",
            "sentence": "While it is recognized that selective AT uptake is required for a functionally active thromboresistant heparin surface, it has also been proposed that other protein interactions may contribute to the observed hemocompatibility of functional surfaces.",
            "startOffset": 51687,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 40890,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The process yields heparin molecules of a reduced molecular weight that contain single reactive aldehyde groups at their reducing terminus.",
            "startOffset": 40751,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 24920,
            "parents": [],
            "secId": "s0005",
            "sentence": "Passive approaches are aimed at reducing the inherent thrombogenicity of the material surface through modification of surface chemistry (e.g. hydrophilicity) or material physical structure (e.g. topography).",
            "startOffset": 24713,
            "title": "Introduction"
        },
        {
            "endOffset": 35446,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "The ASTUTE\u00ae Advanced Heparin Coating was developed by BioInteractions Ltd. and is licensed to Medtronic as the Trillium\u00ae Biosurface.",
            "startOffset": 35314,
            "title": "BioInteractions ASTUTE\u00ae Advanced Heparin Coating/Medtronic Trillium\u00ae Biosurface"
        },
        {
            "endOffset": 47229,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0085",
            "sentence": "Reduced activation can be attributed to the overall considerable reduction of platelet adherence, as well as to the inhibition of platelet stimulating factors such as thrombin.",
            "startOffset": 47053,
            "title": "Reduced platelet adherence and activation"
        },
        {
            "endOffset": 53402,
            "parents": [],
            "secId": "s0100",
            "sentence": "The ability to preserve antithrombin (AT) uptake under physiological conditions is a key attribute required for creating a functionally active heparin coated surface.",
            "startOffset": 53236,
            "title": "Product considerations"
        },
        {
            "endOffset": 63876,
            "parents": [],
            "secId": "s0130",
            "sentence": "Serology studies on the occurrence of anti-PF4/heparin antibodies over time in patients with devices coated with the CBAS Heparin Surface have provided insight as to whether the presence of the CBAS Heparin Surface affects the rate of anti-PF4/heparin antibody seroconversion.",
            "startOffset": 63600,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 67305,
            "parents": [],
            "secId": "s0135",
            "sentence": "AMC THROMBOSHIELD\u00ae is a registered trademark of Edwards Lifesciences, LLC.",
            "startOffset": 67231,
            "title": "Conclusions"
        },
        {
            "endOffset": 58968,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0480": {
                    "endOffset": 58967,
                    "startOffset": 58963
                }
            },
            "secId": "s0120",
            "sentence": "Even with these improvements, acute thrombosis rates were still between 1% and 3% [96].",
            "startOffset": 58881,
            "title": "Coronary stents"
        },
        {
            "endOffset": 67567,
            "parents": [],
            "secId": "s0135",
            "sentence": "CHS\u2122 is a trademark of Corline Systems AB",
            "startOffset": 67526,
            "title": "Conclusions"
        },
        {
            "endOffset": 47892,
            "parents": [],
            "secId": "s0090",
            "sentence": "Only end-point attached heparin conferred thromboresistance in a sensitive recirculating blood loop model using freshly collected non-anticoagulated human blood.",
            "startOffset": 47731,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 60209,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0125",
            "sentence": "Synthetic vascular grafts have a long history of use as \u201coff the shelf\u201d alternatives to autologous vein for peripheral bypass of diseased vessels.",
            "startOffset": 60063,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 62190,
            "parents": [],
            "refoffsets": {
                "bb0565": {
                    "endOffset": 62189,
                    "startOffset": 62184
                }
            },
            "secId": "s0130",
            "sentence": "HIT is a transient, antibody-mediated hypercoagulability state that can be life-threatening with an incidence rate of < 1\u20135% in surgical patients [113].",
            "startOffset": 62038,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 39460,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0050",
            "sentence": "Technical information on the properties of the surface, including biochemical evidence of surface heparin functionality, has not been found in the published literature.",
            "startOffset": 39292,
            "title": "Perouse POLYMAILLE\u00ae Flow Plus Heparin"
        },
        {
            "endOffset": 67632,
            "parents": [],
            "secId": "s0135",
            "sentence": "Flowline BIPORE\u00ae Heparin is a registered trademark of Jotec, GmbH",
            "startOffset": 67567,
            "title": "Conclusions"
        },
        {
            "endOffset": 24393,
            "parents": [],
            "secId": "s0005",
            "sentence": "In some cases, for example in patients with coronary stents, mechanical heart valves, and left ventricular assist devices, chronic pharmacological inhibition with antiplatelet or anticoagulant drugs is required to protect against thrombotic complications.",
            "startOffset": 24138,
            "title": "Introduction"
        },
        {
            "endOffset": 30808,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 30652,
                    "startOffset": 30645
                },
                "bb0100": {
                    "endOffset": 30652,
                    "startOffset": 30645
                },
                "bb0105": {
                    "endOffset": 30652,
                    "startOffset": 30645
                },
                "bb0110": {
                    "endOffset": 30652,
                    "startOffset": 30645
                },
                "bb0115": {
                    "endOffset": 30652,
                    "startOffset": 30645
                }
            },
            "secId": "s0010",
            "sentence": "However, heparin in the blood stream is quickly cleared from circulation through a combination of saturable cell-based binding and non-saturable renal clearance [19\u201323], with an average half-life of approximately 60 min for unfractionated heparin (UFH) and longer a longer half-life for low molecular weight heparins (LMWH).",
            "startOffset": 30484,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 53598,
            "parents": [],
            "secId": "s0100",
            "sentence": "While robust in vitro data in model systems are important, there are other important considerations for development of a heparin coating to be used as part of an implantable device in the clinic.",
            "startOffset": 53403,
            "title": "Product considerations"
        },
        {
            "endOffset": 55668,
            "parents": [],
            "secId": "s0100",
            "sentence": "Published data on long-term in vivo durability of other covalent heparin coating technologies could not be found.",
            "startOffset": 55555,
            "title": "Product considerations"
        },
        {
            "endOffset": 58502,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0455": {
                    "endOffset": 58501,
                    "startOffset": 58497
                }
            },
            "secId": "s0115",
            "sentence": "Application of the CBAS Heparin Surface to VADs developed by Berlin Heart GmbH reduced clot deposition within the pump and lengthened the duration that patients could be effectively maintained on the VAD [91].",
            "startOffset": 58293,
            "title": "Ventricular assist devices"
        },
        {
            "endOffset": 40516,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The technology has been used in a variety of applications including CPB equipment, hemodialysis catheters, ventricular assist devices, vascular stents, stent grafts, and vascular grafts.",
            "startOffset": 40330,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 37937,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0035",
            "sentence": "The technology is being investigated to treat biologic products, including cells, to improve therapies in regenerative medicine by shielding transplanted organs and cells from adverse immune reactions and reducing the inflammatory reaction to implanted collagen matrices.",
            "startOffset": 37666,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 26657,
            "parents": [],
            "secId": "s0010",
            "sentence": "Activation of platelets by a variety of stimuli triggers complex pathways that result in platelet aggregation and the release of potent pro-thrombotic molecules.",
            "startOffset": 26496,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 32134,
            "parents": [],
            "refoffsets": {
                "bb0015": {
                    "endOffset": 32133,
                    "startOffset": 32128
                },
                "bb0030": {
                    "endOffset": 32133,
                    "startOffset": 32128
                }
            },
            "secId": "s0015",
            "sentence": "Other elution-based technologies have been described in previous reviews [3,6].",
            "startOffset": 32055,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 48662,
            "parents": [],
            "secId": "s0090",
            "sentence": "It is important to note that these chemistries may still be viable approaches to retaining some functional activity of the heparin molecules, but the reaction conditions may need to be carefully manipulated so as to minimize interference with the AT binding site.",
            "startOffset": 48399,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 26495,
            "parents": [],
            "secId": "s0010",
            "sentence": "Platelets, small anuclear cells that circulate in blood in ranges from 150 \u00d7 106/mL to 400 \u00d7 106/mL are a critical component of hemostasis.",
            "startOffset": 26356,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 35873,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0145": {
                    "endOffset": 35872,
                    "startOffset": 35868
                }
            },
            "secId": "s0025",
            "sentence": "The coating is described as non-eluting, and data published by the manufacturer describes functional activity of the surface as measured by specific uptake of antithrombin (AT) [29].",
            "startOffset": 35691,
            "title": "BioInteractions ASTUTE\u00ae Advanced Heparin Coating/Medtronic Trillium\u00ae Biosurface"
        },
        {
            "endOffset": 36223,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "The BIOLINE\u00ae Heparin Coating was originally developed by Jostra AG and is now a technology owned by Maquet Medical (Getinge Group) and incorporated into CPB equipment and vascular grafts.",
            "startOffset": 36036,
            "title": "Maquet BIOLINE\u00ae Coating"
        },
        {
            "endOffset": 32711,
            "parents": [],
            "secId": "s0015",
            "sentence": "Each repeating disaccharide unit offers at least one carboxyl and hydroxyl functional group which may be activated and subsequently attached to a compatible functional group on the target surface.",
            "startOffset": 32515,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 49874,
            "parents": [],
            "refoffsets": {
                "bb0170": {
                    "endOffset": 49873,
                    "startOffset": 49866
                },
                "bb0185": {
                    "endOffset": 49873,
                    "startOffset": 49866
                }
            },
            "secId": "s0090",
            "sentence": "Similar plateau-like effects were also identified when studying other heparin coatings for which AT uptake data was available [34,37].",
            "startOffset": 49740,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 33769,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 33768,
                    "startOffset": 33764
                }
            },
            "secId": "s0015",
            "sentence": "Thus simply achieving covalent bonding of heparin to a surface may not be sufficient to produce active thromboresistance on the surface [25].",
            "startOffset": 33628,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 34459,
            "parents": [],
            "secId": "s0015",
            "sentence": "An immobilization method that is durable and retains the catalytic function of heparin has the potential to confer thromboresistance to a surface for extended periods of time.",
            "startOffset": 34284,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 67133,
            "parents": [],
            "secId": "s0135",
            "sentence": "GORE\u00ae and PROPATEN\u00ae are registered trademarks of W.L. Gore & Associates, Inc.",
            "startOffset": 67056,
            "title": "Conclusions"
        },
        {
            "endOffset": 31284,
            "parents": [],
            "secId": "s0015",
            "sentence": "A partial list of commercial heparin coating technologies used in the medical device industry is provided in Table 1.",
            "startOffset": 31167,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 58019,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0450": {
                    "endOffset": 58018,
                    "startOffset": 58014
                }
            },
            "secId": "s0110",
            "sentence": "In a meta-analysis that compared the CBAS Heparin Surface with the an ionically bonded heparin surface (DURAFLO II\u00ae) and uncoated circuits, there was a clear benefit associated with the heparin coated circuits, and a greater magnitude and significance associated with the CBAS Heparin coated circuits [90].",
            "startOffset": 57713,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 67687,
            "parents": [],
            "secId": "s0135",
            "sentence": "PHOTOLINK\u00ae is a registered trademark of Surmodics, Inc.",
            "startOffset": 67632,
            "title": "Conclusions"
        },
        {
            "endOffset": 27851,
            "parents": [],
            "secId": "s0010",
            "sentence": "The protein clotting factors are a set of structurally similar serine proteases that circulate in the plasma as inactive proenzymes.",
            "startOffset": 27719,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 49377,
            "parents": [],
            "refoffsets": {
                "bb0210": {
                    "endOffset": 49376,
                    "startOffset": 49372
                }
            },
            "secId": "s0090",
            "sentence": "Based on the process used for the CBAS Heparin Surface, the data pointed to preserved functional activity in the low single pmol of AT uptake per cm2 surface area of material [42].",
            "startOffset": 49197,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 49739,
            "parents": [],
            "secId": "s0090",
            "sentence": "This suggests that beyond a certain density of functional activity on the surface, effective thromboresistance is achieved and there may be little additional benefit gained from greater surface concentration of AT.",
            "startOffset": 49525,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 38671,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0045",
            "sentence": "Surmodics, Inc. developed a photolinking technology that serves as a platform for covalent immobilization of a variety of molecules.",
            "startOffset": 38539,
            "title": "Surmodics Photolink\u00ae Heparin Coating"
        },
        {
            "endOffset": 34921,
            "parents": [],
            "secId": "s0020",
            "sentence": "Of those commercial covalent chemistries, even fewer have demonstrable evidence of surface heparin bioactivity.",
            "startOffset": 34810,
            "title": "Commercial heparin coating technologies"
        },
        {
            "endOffset": 42136,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0205": {
                    "endOffset": 42135,
                    "startOffset": 42128
                },
                "bb0210": {
                    "endOffset": 42135,
                    "startOffset": 42128
                },
                "bb0215": {
                    "endOffset": 42135,
                    "startOffset": 42128
                },
                "bb0220": {
                    "endOffset": 42135,
                    "startOffset": 42128
                }
            },
            "secId": "s0060",
            "sentence": "Biochemical evidence of surface heparin functionality as measured by the specific uptake of AT has been demonstrated in multiple studies [41\u201344].",
            "startOffset": 41991,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 42906,
            "parents": [],
            "secId": "s0065",
            "sentence": "An illustrative comparison and summary of basic mechanisms of freely soluble heparin, the natural heparan sulfate of the endothelium, and EPA-heparin is shown in Fig. 3.",
            "startOffset": 42737,
            "title": "Mechanism and properties of covalent heparin surfaces"
        },
        {
            "endOffset": 56714,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0270": {
                    "endOffset": 56713,
                    "startOffset": 56703
                },
                "bb0295": {
                    "endOffset": 56672,
                    "startOffset": 56662
                },
                "bb0385": {
                    "endOffset": 56672,
                    "startOffset": 56662
                },
                "bb0390": {
                    "endOffset": 56672,
                    "startOffset": 56662
                },
                "bb0395": {
                    "endOffset": 56713,
                    "startOffset": 56703
                },
                "bb0400": {
                    "endOffset": 56713,
                    "startOffset": 56703
                },
                "bb0405": {
                    "endOffset": 56713,
                    "startOffset": 56703
                },
                "bb0410": {
                    "endOffset": 56713,
                    "startOffset": 56703
                }
            },
            "secId": "s0110",
            "sentence": "Application of the CBAS Heparin Surface to blood contacting equipment of extracorporeal circuits resulted in significant reductions in clotting factor, complement activation, cellular inflammatory markers, and platelet activation in animal models [59,77,78] and in human clinical studies [54,79\u201382].",
            "startOffset": 56415,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 63041,
            "parents": [],
            "refoffsets": {
                "bb0575": {
                    "endOffset": 63040,
                    "startOffset": 63035
                }
            },
            "secId": "s0130",
            "sentence": "However if antibodies are already in circulation, as a result of recent heparin administration, re-exposure to heparin accelerates thrombocytopenia [115].",
            "startOffset": 62887,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 41652,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The Carmeda approach of end-point attachment is predicated on the availability of relatively high affinity AT-binding preparations of heparin and the principle of preserving the ability of heparin to bind AT.",
            "startOffset": 41444,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 44584,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 44374,
                    "startOffset": 44370
                }
            },
            "secId": "s0075",
            "sentence": "In a whole human blood in vitro model examining the CBAS Heparin Surface, Gore et al. [25] also noted the absence of thrombin-antithrombin (TAT) complexes and low levels of fluid phase thrombin activation markers in blood that had recirculated over end-point attached heparin for a period of an hour.",
            "startOffset": 44284,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 31781,
            "parents": [],
            "secId": "s0015",
            "sentence": "The release rate of heparin from the surface may be tailored through physical entrapment or ionic binding of heparin to the surface.",
            "startOffset": 31649,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 33304,
            "parents": [],
            "refoffsets": {
                "bb0130": {
                    "endOffset": 33303,
                    "startOffset": 33299
                }
            },
            "secId": "s0015",
            "sentence": "Periodate oxidation of vicinal diols introduces aldehydes along the heparin chain, which may also be linked to an aminated surface by reductive amination [26].",
            "startOffset": 33145,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 64172,
            "parents": [],
            "refoffsets": {
                "bb0590": {
                    "endOffset": 64171,
                    "startOffset": 64162
                },
                "bb0595": {
                    "endOffset": 64171,
                    "startOffset": 64162
                }
            },
            "secId": "s0130",
            "sentence": "Two separate studies examining a total of 87 patients who received ventricular assist devices (VAD) showed no difference in the occurrence of anti-PF4/heparin antibodies in groups who received the devices with the CBAS Heparin Surface compared with those who received uncoated devices [118,119].",
            "startOffset": 63877,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 31648,
            "parents": [],
            "secId": "s0015",
            "sentence": "Release-based approaches are essentially drug delivery systems that can prevent local device-related thrombus acutely.",
            "startOffset": 31530,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 45094,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0175": {
                    "endOffset": 45093,
                    "startOffset": 45089
                }
            },
            "secId": "s0075",
            "sentence": "Surfaces produced with high heparin density but low AT uptake were efficient in the uptake of FXII, but failed to promote its inhibition [35].",
            "startOffset": 44952,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 28757,
            "parents": [],
            "secId": "s0010",
            "sentence": "Thrombin converts soluble fibrinogen into insoluble fibrin, which polymerizes into an insoluble fibrous network.",
            "startOffset": 28645,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 38383,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0040",
            "sentence": "Additionally, no published data providing biochemical evidence of surface heparin functionality could be found.",
            "startOffset": 38272,
            "title": "Flowline BIPORE\u00ae Heparin Surface"
        },
        {
            "endOffset": 56414,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0110",
            "sentence": "In addition, longer term circulation on extracorporeal membrane oxygenation (ECMO) is also complicated by bleeding complications due to chronic pharmacologic anticoagulation required to prevent circuit thrombosis.",
            "startOffset": 56201,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 60473,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0125",
            "sentence": "As a result ePTFE grafts are considered a suitable prosthetic when autologous saphenous vein is not available.",
            "startOffset": 60363,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 62603,
            "parents": [],
            "secId": "s0130",
            "sentence": "The immunological features of HIT are somewhat unique.",
            "startOffset": 62549,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 28324,
            "parents": [],
            "refoffsets": {
                "bb0055": {
                    "endOffset": 28323,
                    "startOffset": 28319
                }
            },
            "secId": "s0010",
            "sentence": "Tissue factor that is released due to vascular injury is the primary initiator of the extrinsic pathway [11].",
            "startOffset": 28215,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 29184,
            "parents": [],
            "refoffsets": {
                "bb0060": {
                    "endOffset": 29183,
                    "startOffset": 29179
                }
            },
            "secId": "s0010",
            "sentence": "AT binds and irreversibly inhibits the active forms of several clotting factors, including thrombin, FXa, FIXa, FXIa, and FXIIa [12].",
            "startOffset": 29051,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 34552,
            "parents": [],
            "secId": "s0015",
            "sentence": "These non-eluting commercialized technologies are the focus of the remainder of this review.",
            "startOffset": 34460,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 61030,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0215": {
                    "endOffset": 61029,
                    "startOffset": 61021
                },
                "bb0540": {
                    "endOffset": 61029,
                    "startOffset": 61021
                }
            },
            "secId": "s0125",
            "sentence": "Early studies of ePTFE vascular grafts coated with the CBAS Heparin Surface demonstrated dramatic reduction in occlusive thrombus (Fig. 6) and significant improvement in patency compared with uncoated control grafts for at least 6 months in vivo [43,108].",
            "startOffset": 60775,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 58136,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0115",
            "sentence": "Ventricular assist devices (VADs) are used to bridge patients for heart transplantation.",
            "startOffset": 58048,
            "title": "Ventricular assist devices"
        },
        {
            "endOffset": 28951,
            "parents": [],
            "secId": "s0010",
            "sentence": "Clotting factor activation is typically accompanied by and promoted by platelet activation, and the resultant thrombus often contains both platelets, fibrin, and other entrapped cells (Fig. 1).",
            "startOffset": 28758,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 29350,
            "parents": [],
            "refoffsets": {
                "bb0065": {
                    "endOffset": 29349,
                    "startOffset": 29345
                }
            },
            "secId": "s0010",
            "sentence": "AT-mediated inhibition of the clotting factors occurs at relatively slow rate, but is accelerated by binding to the polysaccharides heparan sulfate and heparin [13].",
            "startOffset": 29185,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 40158,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0185": {
                    "endOffset": 40157,
                    "startOffset": 40150
                },
                "bb0190": {
                    "endOffset": 40157,
                    "startOffset": 40150
                }
            },
            "secId": "s0055",
            "sentence": "Published data have demonstrated functional activity of the heparin surface by specific uptake of AT [37,38].",
            "startOffset": 40049,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 66950,
            "parents": [],
            "secId": "s0135",
            "sentence": "Although there continue to be development and advances in new and novel coating technologies for blood-contacting medical devices, functionally active non-eluting heparin bonding remains a viable and effective approach for enhancing the hemocompatibility of medical devices.",
            "startOffset": 66676,
            "title": "Conclusions"
        },
        {
            "endOffset": 39874,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0055",
            "sentence": "This is followed by grafting a copolymer to the poly(vinylsiloxane) followed by a third layer consisting of polyethyleneimine which is covalently attached to the copolymer.",
            "startOffset": 39702,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 35232,
            "parents": [],
            "secId": "s0020",
            "sentence": "The following provides an overview of several relevant commercial non-eluting heparin coatings.",
            "startOffset": 35137,
            "title": "Commercial heparin coating technologies"
        },
        {
            "endOffset": 59765,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0480": {
                    "endOffset": 59566,
                    "startOffset": 59562
                },
                "bb0515": {
                    "endOffset": 59764,
                    "startOffset": 59759
                }
            },
            "secId": "s0120",
            "sentence": "In a large single center retrospective study, significant reductions in thrombosis rates were observed for the stents coated with the CBAS Heparin Surface compared with bare metal stents [96], however registry data from a larger patient population did not demonstrate significant differences between coronary stents coated with the CBAS Heparin Surface and uncoated bare metal stents [103].",
            "startOffset": 59375,
            "title": "Coronary stents"
        },
        {
            "endOffset": 33474,
            "parents": [],
            "secId": "s0015",
            "sentence": "It is important to recognize that covalent immobilization of heparin to a material is not a guarantee that the immobilized heparin will retain its anticoagulant activity.",
            "startOffset": 33304,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 39599,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0055",
            "sentence": "The Hepamed\u2122 coating developed by Medtronic was a covalent heparin coating applied to coronary stents.",
            "startOffset": 39497,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 25488,
            "parents": [],
            "secId": "s0005",
            "sentence": "It was observed that by temporarily immobilizing the anticoagulant drug heparin at the device surface, there was marked reduction in thrombus formation on materials implanted into the vena cava.",
            "startOffset": 25294,
            "title": "Introduction"
        },
        {
            "endOffset": 32957,
            "parents": [],
            "secId": "s0015",
            "sentence": "This may be achieved by direct chemical activation of the surface to introduce complementary functional groups for immobilization of heparin, or through application of an intermediary priming matrix to which the heparin can be covalently linked.",
            "startOffset": 32712,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 46845,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0240": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0285": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0290": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0310": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0315": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0320": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0325": {
                    "endOffset": 46844,
                    "startOffset": 46825
                },
                "bb0330": {
                    "endOffset": 46844,
                    "startOffset": 46825
                }
            },
            "secId": "s0085",
            "sentence": "In vitro recirculatory models, in which platelets are counted before and after exposure and biomarkers of platelet activation (e.g. beta-thromboglobulin and platelet factor 4) were measured in plasma, demonstrated that EPA-heparin surfaces result in reduced platelet adhesion and activation compared with control materials [25,48,57,58,62\u201366].",
            "startOffset": 46502,
            "title": "Reduced platelet adherence and activation"
        },
        {
            "endOffset": 55554,
            "parents": [],
            "refoffsets": {
                "bb0380": {
                    "endOffset": 55553,
                    "startOffset": 55549
                }
            },
            "secId": "s0100",
            "sentence": "Durability of the surface is further supported by anecdotal reports of retained functionally active AT uptake by CBAS Heparin Surfaces in explants of the GORE\u00ae PROPATEN\u00ae Vascular Graft after implant periods of up to 8 years [76].",
            "startOffset": 55325,
            "title": "Product considerations"
        },
        {
            "endOffset": 48129,
            "parents": [],
            "secId": "s0090",
            "sentence": "Heparin attached by multiple covalent bonds using the common carboxylic reactive linker EDC failed to preserve thromboresistance, as did periodate oxidized heparin, which creates multiple aldehyde functionality within heparin molecules.",
            "startOffset": 47893,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 57581,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "refoffsets": {
                "bb0440": {
                    "endOffset": 57580,
                    "startOffset": 57576
                }
            },
            "secId": "s0110",
            "sentence": "However, meta-analyses of numerous studies, including both heparin eluting and covalently bonded heparin circuits have demonstrated improved outcomes with heparin-coated circuits compared to uncoated circuits [88].",
            "startOffset": 57367,
            "title": "Extracorporeal circulation equipment"
        },
        {
            "endOffset": 60631,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0125",
            "sentence": "As diameter decreases below 6 mm, patency of synthetic vascular grafts is generally viewed as suboptimal, particularly in bypass applications below the knee.",
            "startOffset": 60474,
            "title": "Vascular grafts"
        },
        {
            "endOffset": 30977,
            "parents": [],
            "secId": "s0015",
            "sentence": "Heparin-coated blood contacting medical devices have been in clinical application for more than three decades.",
            "startOffset": 30867,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 50626,
            "parents": [],
            "secId": "s0090",
            "sentence": "It is important to recognize that the relationship between specific AT uptake values and certain performance attributes attributed to one type of heparin surface bonding technology may not be universal and should not be assumed to be the same for other heparin technologies.",
            "startOffset": 50352,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 64957,
            "parents": [],
            "refoffsets": {
                "bb0615": {
                    "endOffset": 64956,
                    "startOffset": 64951
                }
            },
            "secId": "s0130",
            "sentence": "Delayed onset HIT is characterized by the presence of antibodies that are capable of heparin-independent platelet activation [123].",
            "startOffset": 64826,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 59156,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0120",
            "sentence": "Before the full emergence of drug eluting coronary stents (DES), the CBAS Heparin Surface and other heparin technologies were evaluated as surface treatments for metallic coronary stents.",
            "startOffset": 58969,
            "title": "Coronary stents"
        },
        {
            "endOffset": 58639,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0120",
            "sentence": "Device-related thrombosis is a potentially life threatening adverse outcome associated with the use of coronary stents.",
            "startOffset": 58520,
            "title": "Coronary stents"
        },
        {
            "endOffset": 36010,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "This technology has been used for coating blood contacting equipment used in cardiopulmonary bypass (CPB) and on hemodialysis catheters.",
            "startOffset": 35874,
            "title": "BioInteractions ASTUTE\u00ae Advanced Heparin Coating/Medtronic Trillium\u00ae Biosurface"
        },
        {
            "endOffset": 34099,
            "parents": [],
            "secId": "s0015",
            "sentence": "In this context, it is relevant to recognize that the standard metric of injectable heparin potency, expressed as International Units (IU) of heparin, is not a useful means of assessing the activity of covalently bonded heparin because the reaction kinetics of bound heparin are drastically different from freely soluble heparin.",
            "startOffset": 33770,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 40048,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0055",
            "sentence": "The heparin used was not depolymerized or enriched for the high affinity fraction of heparin molecules.",
            "startOffset": 39945,
            "title": "Medtronic Hepamed\u2122 Heparin Coating"
        },
        {
            "endOffset": 23639,
            "parents": [],
            "secId": "s0005",
            "sentence": "The activation of blood defense mechanisms upon exposure to biomaterials poses a challenge to the design and performance of blood contacting medical devices.",
            "startOffset": 23482,
            "title": "Introduction"
        },
        {
            "endOffset": 23852,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 23851,
                    "startOffset": 23846
                },
                "bb0010": {
                    "endOffset": 23851,
                    "startOffset": 23846
                }
            },
            "secId": "s0005",
            "sentence": "Activation of the coagulation cascade, complement system, cellular inflammatory mechanisms, and platelets are among the key adverse reactions of blood that may compromise the performance of medical devices [1,2].",
            "startOffset": 23640,
            "title": "Introduction"
        },
        {
            "endOffset": 31166,
            "parents": [],
            "secId": "s0015",
            "sentence": "A comprehensive description and comparison of the various commercial technologies has not been possible due to the lack of published detailed technical information on all the technologies.",
            "startOffset": 30978,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 50753,
            "parents": [],
            "secId": "s0090",
            "sentence": "While AT uptake is a key measure of surface functionality, heparin is not the only entity exposed on a heparin coated surface.",
            "startOffset": 50627,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 26064,
            "parents": [],
            "secId": "s0005",
            "sentence": "Of the various heparin-based technologies, the CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface; Carmeda AB, Upplands V\u00e4sby, Sweden), has the most extensive publication history describing both basic biochemical mechanisms and clinical applications.",
            "startOffset": 25815,
            "title": "Introduction"
        },
        {
            "endOffset": 41444,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0200": {
                    "endOffset": 41443,
                    "startOffset": 41439
                }
            },
            "secId": "s0060",
            "sentence": "The end result is a permanently immobilized, stable, non-leaching coating that is a few hundred nanometers thick [40].",
            "startOffset": 41326,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 41990,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 41989,
                    "startOffset": 41985
                }
            },
            "secId": "s0060",
            "sentence": "Its development was spurred by a combination of events: the early and discouraging attempts to permanently bind heparin to surfaces, which often failed to preserve heparin's anticoagulant function, as well as increased understanding of heparin's mechanism of action, including the discovery of the critical pentasaccharide sequence [15].",
            "startOffset": 41653,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 46501,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0085",
            "sentence": "An additional feature of immobilized heparin is the reported resistance to platelet adhesion and activation.",
            "startOffset": 46393,
            "title": "Reduced platelet adherence and activation"
        },
        {
            "endOffset": 66492,
            "parents": [],
            "secId": "s0135",
            "sentence": "Numerous studies have demonstrated that retaining the anticoagulant activity of heparin, by preserving the ability to bind antithrombin and catalyze the inhibition of clotting factors, is central to the design of a functional heparin surface.",
            "startOffset": 66250,
            "title": "Conclusions"
        },
        {
            "endOffset": 35579,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0025",
            "sentence": "The coating consists of a hydrophilic priming layer (a modified polyethyleneimine) that enables adsorption to a variety of surfaces.",
            "startOffset": 35447,
            "title": "BioInteractions ASTUTE\u00ae Advanced Heparin Coating/Medtronic Trillium\u00ae Biosurface"
        },
        {
            "endOffset": 58240,
            "parents": [
                {
                    "id": "s0105",
                    "title": "Performance of CBAS Heparin Surfaces in vivo"
                }
            ],
            "secId": "s0115",
            "sentence": "Systemic treatment with anticoagulants is required to mitigate against clot formation in the equipment.",
            "startOffset": 58137,
            "title": "Ventricular assist devices"
        },
        {
            "endOffset": 62751,
            "parents": [],
            "secId": "s0130",
            "sentence": "The immune response is also not anamnestic.",
            "startOffset": 62708,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 49196,
            "parents": [],
            "secId": "s0090",
            "sentence": "In an in vitro recirculatory model, Sanchez et al. examined the relationship between the amount of AT uptake on the surface and FXII activation and plasma clotting time.",
            "startOffset": 49027,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 54601,
            "parents": [],
            "secId": "s0100",
            "sentence": "In addition, functionally active heparin must be sufficiently uniform across the surface area of the material so that the thromboresistant performance of the surface is not compromised by uncoated regions or by exposure of any other component of the surface.",
            "startOffset": 54343,
            "title": "Product considerations"
        },
        {
            "endOffset": 66675,
            "parents": [],
            "secId": "s0135",
            "sentence": "Not all approaches to heparin bonding achieve the prerequisite of preserving antithrombin binding, and it is thus important to recognize that not all heparin coatings are equivalent.",
            "startOffset": 66493,
            "title": "Conclusions"
        },
        {
            "endOffset": 26355,
            "parents": [],
            "secId": "s0010",
            "sentence": "Thrombus formation is the result of two interdependent mechanisms, platelets and circulating protein clotting factors.",
            "startOffset": 26237,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 43068,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0070",
            "sentence": "The reaction kinetics for an immobilized heparin surface are distinctly different from those of systemically administered heparin in solution.",
            "startOffset": 42926,
            "title": "Reaction kinetics"
        },
        {
            "endOffset": 43930,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 43913,
                    "startOffset": 43900
                },
                "bb0135": {
                    "endOffset": 43929,
                    "startOffset": 43922
                },
                "bb0205": {
                    "endOffset": 43929,
                    "startOffset": 43922
                },
                "bb0235": {
                    "endOffset": 43913,
                    "startOffset": 43900
                },
                "bb0240": {
                    "endOffset": 43913,
                    "startOffset": 43900
                }
            },
            "secId": "s0075",
            "sentence": "Experiments conducted using recirculating in vitro blood and plasma contact models have demonstrated that materials coated with EPA-heparin reduce the formation of activated thrombin [25,27,47,48] and FXa [27,41].",
            "startOffset": 43717,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 47574,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 47573,
                    "startOffset": 47557
                },
                "bb0205": {
                    "endOffset": 47573,
                    "startOffset": 47557
                },
                "bb0210": {
                    "endOffset": 47573,
                    "startOffset": 47557
                },
                "bb0220": {
                    "endOffset": 47573,
                    "startOffset": 47557
                },
                "bb0340": {
                    "endOffset": 47573,
                    "startOffset": 47557
                }
            },
            "secId": "s0090",
            "sentence": "The ability of heparin to inhibit the clotting cascade as well as reduce platelet attachment is dependent on the specific uptake of antithrombin (AT) by the immobilized heparin [25,41,42,44,68].",
            "startOffset": 47380,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 34809,
            "parents": [],
            "secId": "s0020",
            "sentence": "While there exist numerous means to immobilize heparin to a substrate, only a relative few technologies have been successfully employed in marketed medical devices, with only a subset designed as non-eluting surfaces.",
            "startOffset": 34592,
            "title": "Commercial heparin coating technologies"
        },
        {
            "endOffset": 47052,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0025": {
                    "endOffset": 47051,
                    "startOffset": 47048
                }
            },
            "secId": "s0085",
            "sentence": "Reduced platelet adhesion is attributed to reduction of fibrinogen deposition produced from a functionally active heparin surface, and the extent of reduction is correlated with the extent of AT uptake [5].",
            "startOffset": 46846,
            "title": "Reduced platelet adherence and activation"
        },
        {
            "endOffset": 44107,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "refoffsets": {
                "bb0175": {
                    "endOffset": 44106,
                    "startOffset": 44099
                },
                "bb0245": {
                    "endOffset": 44106,
                    "startOffset": 44099
                }
            },
            "secId": "s0075",
            "sentence": "In similar models it was also identified that the intrinsic clotting cascade, in which FXII activation is a key upstream trigger, is an important target of EPA-heparin [35,49].",
            "startOffset": 43931,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 67526,
            "parents": [],
            "secId": "s0135",
            "sentence": "CORLINE\u00ae is a registered trademark of Corline Systems AB",
            "startOffset": 67470,
            "title": "Conclusions"
        },
        {
            "endOffset": 50026,
            "parents": [],
            "refoffsets": {
                "bb0210": {
                    "endOffset": 50025,
                    "startOffset": 50021
                }
            },
            "secId": "s0090",
            "sentence": "It was proposed that steric hindrance as result of heparin interaction with plasma proteins, including AT, may have been a contributing mechanism [42].",
            "startOffset": 49875,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 67470,
            "parents": [],
            "secId": "s0135",
            "sentence": "BIOLINE\u00ae is a registered trademark of Maquet Cardiovascular, LLC (Maquet Getinge Group)",
            "startOffset": 67383,
            "title": "Conclusions"
        },
        {
            "endOffset": 41235,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0060",
            "sentence": "The amines are introduced onto the surface by application of base matrix that consists of alternating layers of the anionic polysaccharide dextran sulfate and the cationic polymer polyethyleneimine (Fig. 2).",
            "startOffset": 41028,
            "title": "CARMEDA\u00ae BioActive Surface (CBAS\u00ae Heparin Surface)"
        },
        {
            "endOffset": 32514,
            "parents": [],
            "refoffsets": {
                "bb0035": {
                    "endOffset": 32513,
                    "startOffset": 32510
                }
            },
            "secId": "s0015",
            "sentence": "By virtue of its strong net negative charge, low pKa due to the abundance of carboxyl and sulfo groups, and variety of chemically active functional groups, heparin can be readily immobilized by different surface conjugation chemistries [7].",
            "startOffset": 32274,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 36475,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0030",
            "sentence": "Detailed technical data on the coating chemistry and demonstration of surface heparin functionality by uptake of AT has not been published.",
            "startOffset": 36336,
            "title": "Maquet BIOLINE\u00ae Coating"
        },
        {
            "endOffset": 47730,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 47591,
                    "startOffset": 47587
                }
            },
            "secId": "s0090",
            "sentence": "Gore et al. [25] conducted a controlled evaluation comparing AT uptake and performance of various heparin surfaces using the same base matrix and material.",
            "startOffset": 47575,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 27407,
            "parents": [],
            "secId": "s0010",
            "sentence": "The phospholipids of the platelet membrane also serve as the substrate for activated clotting factors, resulting in local amplification of the coagulation cascade.",
            "startOffset": 27244,
            "title": "Coagulation and heparin mechanism of action"
        },
        {
            "endOffset": 49027,
            "parents": [],
            "secId": "s0090",
            "sentence": "The resistance to platelet binding may thus be the indirect result of the action of heparin on the coagulation cascade, not solely due to the negative charge imparted by heparin.",
            "startOffset": 48849,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 66249,
            "parents": [],
            "secId": "s0135",
            "sentence": "Because it is not a drug releasing technology, the mechanisms of a permanently bonded heparin surface are different from those of device-based drug releasing systems, and it follows that design considerations also differ.",
            "startOffset": 66028,
            "title": "Conclusions"
        },
        {
            "endOffset": 34283,
            "parents": [],
            "refoffsets": {
                "bb0135": {
                    "endOffset": 34282,
                    "startOffset": 34278
                }
            },
            "secId": "s0015",
            "sentence": "For this reason it is appropriate to assess the functional activity of covalently bonded heparin by measuring the capacity of the surface to specifically uptake AT from solution [27].",
            "startOffset": 34100,
            "title": "Approaches to heparin immobilization for thromboresistance"
        },
        {
            "endOffset": 44714,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0075",
            "sentence": "This was consistent with efficient inhibition of the clotting cascade upstream of thrombin, likely through the intrinsic pathway.",
            "startOffset": 44585,
            "title": "Inhibition of activated clotting factors"
        },
        {
            "endOffset": 49524,
            "parents": [],
            "secId": "s0090",
            "sentence": "Above the threshold value of AT uptake, no additional inhibition of FXIIa could be detected, and plasma clotting times were not further increased.",
            "startOffset": 49378,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 43212,
            "parents": [
                {
                    "id": "s0065",
                    "title": "Mechanism and properties of covalent heparin surfaces"
                }
            ],
            "secId": "s0070",
            "sentence": "Functional non-eluting heparin surfaces would not be expected to impact clotting in the bulk, and hence have no systemic anticoagulant effects.",
            "startOffset": 43069,
            "title": "Reaction kinetics"
        },
        {
            "endOffset": 48848,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 48766,
                    "startOffset": 48759
                },
                "bb0170": {
                    "endOffset": 48847,
                    "startOffset": 48840
                },
                "bb0185": {
                    "endOffset": 48847,
                    "startOffset": 48840
                },
                "bb0220": {
                    "endOffset": 48766,
                    "startOffset": 48759
                }
            },
            "secId": "s0090",
            "sentence": "Resistance to platelet adhesion has also been shown to be dependent on AT uptake of EPA-heparin [25,44] as well several other heparin coatings which have demonstrated AT uptake [34,37].",
            "startOffset": 48663,
            "title": "Importance of preserving at binding"
        },
        {
            "endOffset": 62548,
            "parents": [],
            "refoffsets": {
                "bb0570": {
                    "endOffset": 62448,
                    "startOffset": 62439
                },
                "bb0575": {
                    "endOffset": 62448,
                    "startOffset": 62439
                },
                "bb0580": {
                    "endOffset": 62448,
                    "startOffset": 62439
                }
            },
            "secId": "s0130",
            "sentence": "It is observed clinically as a severe decline in circulating platelets sometimes accompanied by thrombosis that follows a well described timeline [114\u2013116], with typical onset of thrombocytopenia occurring between 5 and 10 days following heparin exposure.",
            "startOffset": 62293,
            "title": "Potential adverse reactions to heparinized surfaces: evidence on Heparin Induced Thrombocytopenia (HIT) associated with heparin-containing medical devices"
        },
        {
            "endOffset": 36917,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Commercial heparin coating technologies"
                }
            ],
            "secId": "s0035",
            "sentence": "One major commercial application of the technology was in coronary stents.",
            "startOffset": 36843,
            "title": "CORLINE\u00ae Heparin Surface (CHS\u2122)"
        },
        {
            "endOffset": 51687,
            "parents": [],
            "refoffsets": {
                "bb0040": {
                    "endOffset": 51686,
                    "startOffset": 51683
                }
            },
            "secId": "s0095",
            "sentence": "Indeed because of the recognized relatively high affinity binding (KD < 10\u2212 6 M) of certain types of proteins, heparin has been used as a vehicle for drug delivery, most notably of growth factors [8].",
            "startOffset": 51487,
            "title": "Protein binding to heparin surfaces"
        },
        {
            "endOffset": 52753,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 52434,
                    "startOffset": 52430
                },
                "bb0360": {
                    "endOffset": 52752,
                    "startOffset": 52748
                }
            },
            "secId": "s0095",
            "sentence": "In a study of EPA-heparin, Gore et al. [25] observed that AT constituted 40% of the total protein uptake from blood after acute contact, but in separate studies also noted the presence of other protease inhibitors such as heparin cofactor II and the absence of fibrinogen, cell adhesive proteins such as fibronectin and vitronectin, and complement proteins [72].",
            "startOffset": 52391,
            "title": "Protein binding to heparin surfaces"
        }
    ],
    "docId": "S0169409X16303210",
    "metadata": {
        "asjc": [
            "3003"
        ],
        "authors": [
            {
                "email": "rbiran@wlgore.com",
                "first": "Roy",
                "initial": "R.",
                "last": "Biran"
            },
            {
                "email": null,
                "first": "Daniel",
                "initial": "D.",
                "last": "Pond"
            }
        ],
        "doi": "10.1016/j.addr.2016.12.002",
        "firstpage": "12",
        "issn": "0169409X",
        "keywords": [
            "Biocompatibility",
            "Biomaterials",
            "Blood compatibility",
            "Coagulation",
            "Heparin",
            "Heparin immobilization",
            "Medical devices",
            "Thromboresistance",
            "Thrombosis"
        ],
        "lastpage": "23",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "PHAR"
        ],
        "title": "Heparin coatings for improving blood compatibility of medical devices"
    }
}